



NATIONAL HEALTH
LABORATORY SERVICE

National Cancer Registry



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

EKURHULENI POPULATION-BASED CANCER REGISTRY 2020 REPORT

Johannesburg, South Africa, March 2022



Copyright © 2022

Citation:

**National Cancer Registry, South Africa. Ekurhuleni Population-Based Cancer Registry
2020 Report. www.ncr.ac.za.**

Compiled by:

Lactatia Motsuku (Epidemiologist)

Dr. Mazvita Muchengeti (Senior Epidemiologist)

Natasha Abraham (Epidemiologist)

Dr Elvira Singh (Head of Department)

Ekurhuleni Population-Based Cancer Registry Surveillance Officers:

Phelade Kale

Mapule Makama

Siphiwe Mpangani

Nelisiwe Fakude

Londiwe Mhlungu

Horatius Simphiwe Javu

Nomthandazo Dube

Clarence Sibiya

Ekurhuleni Population-Based Cancer Registry

National Cancer Registry, National Health Laboratory Service

1 Modderfontein Road, Sandringham

Johannesburg

South Africa

2131

Tel: +27 11 555 0548

Fax to email: +27 11 386 6516

Website: www.ncr.ac.za

DISCLAIMER

This report includes all reported cancer cases for Ekurhuleni residents diagnosed from 1st January 2020 to 31st December 2020 as recorded in the Ekurhuleni population-based cancer registry (EPBCR). The information reflects the data at the time of closing the 2020 database for cleaning and analysis on the 31st of October 2021. The EPBCR continues to receive and collect additional data; therefore, the data may be updated as and when necessary. Special requests for data should be directed to the NCR administrator, Ms Evelyn Nkosi, EvelynN@nicd.ac.za.

DEDICATION

This Ekurhuleni Population-based Cancer Registry 2020 report is dedicated to the late Dr Elvira Singh (1976 – 2022).

TABLE OF CONTENTS

DISCLAIMER	iii
DEDICATION	iv
LIST OF TABLES	vi
LIST OF FIGURES	vi
LIST OF APPENDICES	vii
Appendix 3: Tables of incidence by site, sex, age group & population group ekurhuleni 2020	vii
ACRONYMS AND ABBREVIATIONS	viii
FOREWORD	ix
In Memoriam – Dr Elvira Singh (08/07/1976 – 26/02/2022)	xi
EXECUTIVE SUMMARY	xiii
INTRODUCTION	1
METHODS	3
Data sources.....	3
Data collection and processes.....	6
Confidentiality.....	8
Statistical analysis	9
RESULTS	10
Overall cancer incidence	10
Comparison with year 2017, 2018, 2019 & 2020	18
Childhood cancers incidence.....	22
Data Quality Indicators.....	23
DISCUSSION	25
ACKNOWLEDGEMENTS	28
REFERENCES	30

APPENDICES	32
Appendix 1: List of Data Sources	32
Appendix 2: South African Cancer Notification Form	33
Appendix 3: Tables of Incidence by site, sex, age group and population	34

LIST OF TABLES

Table 1: Summary statistics for all cancers in Men, Ekurhuleni (2020)	11
Table 2: Summary statistics for all cancers in Women, Ekurhuleni (2020)	12
Table 3: Childhood cancers 2020	22
Table 4: Percentage of cases Morphologically Verified, diagnosed clinically or diagnosed by Death Certificate Only	23

LIST OF FIGURES

Figure 1: Ekurhuleni Population-based cancer registry data sources map	5
Figure 2: Ekurhuleni Population Based Cancer Registry data flow diagram	7
Figure 3:: Percentage of cancer cases by gender and race.....	10
Figure 4: Frequency of most common cancers in males.....	13
Figure 5: Age Standardised Incidence Rates for common cancers in males	14
Figure 6: Frequency of top 10 common cancers in females	15
Figure 7: Age standardised incidence rates for the common cancers in females	16
Figure 8: ASR of common cancers in men by population group	Error! Bookmark not defined.
Figure 9: ASR of common cancers in women by population group.....	18
Figure 10:Age standardised incidence rates of the most common cancers in men, 2017-2020	19

Figure 11: Age standardised incidence rates of the most common cancers in women, 2017-2020.....	20
Figure 12: Number of Cancer cases reported by by year and gender	21

LIST OF APPENDICES

Appendix 1: List of Data Sources

Appendix 2: South African cancer notification form

Appendix 3: Tables of incidence by site, sex, age group & population group ekurhuleni 2020

ACRONYMS AND ABBREVIATIONS

AFCRN	: African Cancer Registry Network
DoH	: Department of Health, South Africa
DoHA	: Department of Home Affairs, South Africa
EPBCR	: Ekurhuleni Population-Based Cancer Registry
IACR	: International Association of Cancer Registries
IARC	: International Agency for Research on Cancer
ICCC	: International Classification of Childhood Cancer
ICDO-3	: International Classification of Diseases for Oncology Third Edition
NCR	: National Cancer Registry, South Africa
POPI Act	: Protection of Personal Information Act, South Africa
SA	: South Africa
SAMRC	: South African Medical Research Council
SAOC	: South African Oncology Consortium
STATSSA	: Statistics, South Africa
UICC	: Union for International Cancer Control
WHO	: World Health Organization
ASR	: Age-Standardised Incidence Rate
WSP	: World Standard Population

FOREWORD

It gives me great pleasure to make public the 2020 annual report of the Ekurhuleni Population-Based Cancer Registry (EPBCR).

The current report on the EPBCR culminates from support from the National Department of Health, the National Institute for Communicable Diseases, the National Health Laboratory Service, and the work of the National Cancer Registry (NCR) to establish South Africa's first urban population-based cancer registry. This is the fourth report to be produced for the EPBCR; previous reports having covered the years 2017, 2018, and 2019 (unpublished due to gross underreporting and underestimation of cancer incidence emanating from the restricted access to hospitals in 2020 due to the COVID-19 pandemic). While this report provides essential information for healthcare planning locally, the vision for the EPBCR has always been to reach benchmark international standards to report South Africa's cancer incidence rates to the International Agency for Research on Cancer (IARC). With each successive year of operations, the EPBCR has achieved progressively better data quality.

This is not to say that there have been no hurdles. Since the COVID-19 pandemic began, routine cancer surveillance has been more challenging. With some hospital wards closed, outpatient clinics suspended and restrictions on the movement of surveillance officers, high quality and complete cancer data collection were hindered. However, it is due to the resilience of the staff of the EPBCR that adequate data were collected between the years 2020 and 2021 resulting in the publication of this report.

I would like to commend the staff and stakeholders of the EPBCR for their ongoing commitment to cancer surveillance during these challenging times. Sadly, at the time of drafting this report, the NCR lost Dr Elvira Singh, our Head of Department. Dr Singh spearheaded the establishment and implementation of the EPBCR, which is the first urban population-based cancer registry in South Africa (SA). With the EPBCR firmly established, the NCR looks forward to continuing the work that Dr Singh started by establishing population-based cancer registries at the outstanding planned three sentinel sites across SA. We are thankful for Dr Singh's commitment to building capacity and ensuring participation of early-career scientists in the operations of the NCR. I am confident that the NCR team will

carry through her vision in making the NCR a centre of excellence for cancer surveillance and research in SA, Africa and indeed the world at large.



Dr Mazvita Muchengeti

Date: 31 March 2022

(Senior Epidemiologist, National Cancer Registry)

In Memoriam – Dr Elvira Singh (08/07/1976 – 26/02/2022)



Dr Elvira Singh (1976-2022)

The National Cancer Registry (NCR), the National Institute for Communicable Diseases (NICD), the National Health Laboratory Service (NHLS) and the greater cancer community in South Africa mourns the untimely passing of the NCR Head of Department, Dr Elvira Singh. She passed away on Saturday, 26 February 2022.

Dr Singh was a respected public health medicine specialist with extensive experience in the fields of cancer surveillance and cancer epidemiology. Upon joining the NHLS in 2009, she worked at the National Institute for Occupational Health (NIOH), and thereafter the NCR. At the time of her passing, Dr Singh was the Head of the National Cancer Registry in South Africa and a valued senior staff member at the NICD. At the NIOH, she gained project management experience through administering large grants allocated to the NHLS from the Centre for Disease Control and Prevention in the United States. These intricate projects involved the careful coordination of diverse groups of researchers and clinicians, together with the management of financial resources and delivering deadline-driven outputs.

Dr Singh was determined to enhance the pathology-based cancer surveillance system, to implement pilot population-based cancer registration and to extend this initiative to three other sentinel surveillance sites throughout the country. The pathology-based cancer registry

has recently managed to accomplish a remarkable 3-year lag time in cancer reporting. The Ekurhuleni Population-Based Cancer Registry (EPBCR) is the first urban population-based cancer registry in South Africa. Dr Singh passionately led a team that produced three years' worth of data from the EPBCR, and was in the process of establishing a second population-based cancer registry in KwaZulu-Natal, in collaboration with colleagues from the University of KwaZulu-Natal.

Dr Singh concentrated on building on the foundation of excellent research initiated at the NCR through the Johannesburg Cancer Study, and by extending the collaborations of the NCR in South Africa and abroad. She was a co-investigator on the ERICA-SA and the MADCaP projects. Furthermore, she was the Principal Investigator for the South African HIV Cancer Match study, managed the grants received for the establishment of the population-based cancer registry, and she navigated the only nationally representative cancer surveillance system in the country to its current successes. As an NCR representative for the Ministerial Advisory Committee on the Prevention and Control of Cancer in South Africa, Dr Singh was instrumental in drafting the South African breast and cervical cancer policies. Under her exemplary leadership, the NCR was an active member of the African Cancer Registry Network and nominated as a Collaborating Centre for Sub-Saharan Africa for childhood cancers, and record linkage by the Global Initiative for Cancer Registry (GICR) Development.

It was an honour to work with her and we will miss her warmth, enthusiasm, beautiful smile and her commitment to strengthening cancer surveillance in Africa.

She is survived by her husband Shaileen, son Mihail and mother Roshni Singh.

She will live in our hearts forever.

EXECUTIVE SUMMARY

It has been more than a decade since the enactment of Regulation No 380 of the National Health Act (Act 61 of 2003), which formally established the NCR as its delegated agency for the collection of cancer surveillance information (3). This regulation made cancer a reportable disease with every healthcare worker obliged to report confirmed cancers to the NCR (3,4). In addition, it mandated the NCR to establish population-based cancer registration for the country which led to the establishment and successful implementation of the EPBCR as a pilot site for population-based cancer surveillance in SA.

Despite the NCR operating pathology-based cancer registration since 1986, population-based cancer registration (PBCR) remains the gold standard for cancer surveillance worldwide. It is through comprehensive and quality cancer data that can only be generated by PBCR that the country can effectively drive cancer policy, decision making, and intervention programmes aimed at reducing cancer cases and deaths. The EPBCR has yielded four years of data since its implementation in 2017.

This report details the fourth year of population-based cancer registration in Ekurhuleni metropolitan municipality, Gauteng province of SA. This includes cancers that were diagnosed between 1st January and 31st December 2020. Data collection for these cancers was conducted in the years 2020 and 2021. Methods of data collection endorsed by the International Agency for Research on Cancer, the International Association of Cancer Registries and the African Cancer Registry Network were employed.

A total of 3131 new cancer cases were registered for the year 2020. The most common cancers registered were prostate, colorectal and bladder cancers among males and cervix, breast, and colorectal cancer among females. Among children (0-14 years) there were 20 cases registered for 2020. Leukaemia was the most common cancer in children.

The unprecedented COVID-19 pandemic in 2020, posed many challenges to public health programmes globally, and the EPBCR was no exception. The overall case finding and data collection for the year 2020 decreased by 33.31% compared with 4695 in 2018. Some of the challenges to name a few were i) restricted access for EPBCR surveillance officers to collect cancer data in health facilities during lockdown, ii) the misinterpretation of POPIA resulting in facilities being less willing to report cancer data and iii) closure of Charlotte Maxeke Johannesburg Academic Hospital (a major data source for EPBCR) due to the fire in 2021. Despite the challenges encountered by the EPBCR surveillance officers in data collection, this

report provides valuable information for key stakeholders to guide decision making, planning of cancer initiatives and intervention programmes, and important data for evaluation of health interventions.

In the 2022/23 financial year, the NCR will continue to strengthen the EPBCR. The main priorities will be i) to submit the EPBCR (2017-2020) to IARC, ii) to initiate real-time data collection for 2022, while consolidating the 2020 and 2021 databases and iii) to enhance the engagement to implement PBCR in KwaZulu-Natal province.

INTRODUCTION

Cancer is a generic term used for a large group of diseases, characterised by abnormal cell growth that can happen at any body part and can later invade the adjoining parts of the body. Cancer remains an important public health challenge and a leading cause of death globally. In 2020, the World Health Organisation (WHO), International Agency for Research on Cancer (IARC) reported an estimated 19.3 million new cancer cases and about 10 million deaths worldwide (1). The distribution of cancer incidence and mortality varies significantly across different regions of the world. Low and middle-income countries (LMICs) are greatly affected and it is estimated that in 2040 about two-thirds of new cancer cases will originate in LMICs (2). The economic implications of the increasing cancer incidence and deaths are catastrophic to both individuals in the community and the public health system (3). Proper evidence-based planning for the future to effectively inform cancer prevention and control policies, intervention programmes and strategies, depends on robust continuous cancer surveillance with quality data (3). It was recognised by many governments during the 2011 United Nations resolution on Non-Communicable Diseases (NCDs) and WHO Global Action for the prevention and control of NCDs for 2013-2020, that population-based cancer registries (PBCRs) are vital components to cancer prevention and control (4). The PBCR gathers information about all cancer cases and deaths for residents within a well-defined geographical area over a period of time (5). The PBCR is the only tool that can provide the best estimation of the true burden of cancer, monitor epidemiological trends, as well as predict the future cancer burden for the country (5).

In 2011, IARC in partnership with international communities launched the Global Initiative for Cancer Registry Development (GICR) in an effort to accelerate PBCR coverage and quality data improvements across the globe (6).

Despite the efforts made by the IARC, there are an estimated 700 cancer registries across the world which cover only about 21% of the world population (7). In the African region, the PBCR coverage is estimated at 11%. In an effort to improve PBCRs coverage and effectiveness of cancer surveillance in sub-Saharan Africa, the International Network for Cancer Treatment and Research (INCTR) established and launched the African Cancer Registry Network (AFCRN) in 2012 (7).

The South African government has made efforts to support the development of PBCR in the country. In 2011, the South African Department of Health enacted Regulation No 380 of the

National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as its delegated agency for the collection of cancer surveillance information (3). This regulation made cancer a reportable disease with every healthcare worker obliged to report confirmed cancers to the NCR (3,4). In addition, it mandated the NCR to establish PBCR for the country. After consultation with local and international cancer surveillance experts, it was decided that a minimum of four population-based cancer registries will be needed to confidently extrapolate national cancer incidence. We established the Ekurhuleni Population-Based Cancer Registry (EPBCR) in Gauteng, as the first urban population-based cancer surveillance site for the country in 2015. This is the fourth cancer incidence report for the EPBCR accounting for all reported cancers diagnosed in 2020.

METHODS

The EPBCR employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN). In short, the EPBCR employs both passive and active surveillance, collecting data on all cancer patients residing in Ekurhuleni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigation.

Data sources

i. Government and Private Hospitals/Healthcare Facilities

The EPBCR has multiple data sources. The data sources extend beyond the borders of the Ekurhuleni metropolitan municipality due to the nature of the South African healthcare referral system. The municipalities do not often have all levels of care (level 1: Primary health care clinic, Community health care centre, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (8). Therefore, patients may be referred out of the municipality to access further diagnosis and management. Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which is not necessarily within the borders of the district in which they reside.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen per cent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, to obtain complete reporting from the Ekurhuleni District's population, the EPBCR also collects data from private hospitals, and clinicians in independent private practice (See Appendix 1 for a comprehensive list of data sources).

ii. Laboratories, Oncology Networks and Associations

SA has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has 268 (as of March 2019) laboratories in nine provinces of SA (9). The other estimated 20% of the population

is covered by private laboratories which include but are not limited to Ampath, Pathcare and Lancet laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer to the NCR's national pathology surveillance programme. The surveillance officers use all the pathology reports received from laboratories together with other data tools (medical files, hospital register, pharmacy list etc.) to identify, trace and register patients from Ekurhuleni metropolitan municipality into the EPBCR.

In addition, The South African Paediatric Oncology Group and the South African Oncology Consortium (SAOC) report their relevant data for residents of Ekurhuleni to the NCR. The surveillance officers (SO) use these data sources to consolidate missing information for patients already registered in the EPBCR database or to trace and notify the patient in conjunction with other data tools from different data sources. Finally, SOs use hospital registers, patient files and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

iii. The Hospice

The SOs visit hospices at regular intervals to consolidate information missing for patients already registered from other data sources such as hospitals, as well as to report any new patients identified.

iv. Vital Statistics (Death Registration)

The Department of Home Affairs (DHA) is the custodian of vital statistics for SA. The Statistics South Africa (STATS SA) also has cleaned vital statistics data for South Africans that can be used to consolidate vital status (i.e. dead/alive) in the EPBCR. However, STATS SA is unable to legally share patient-level data with other official organisations. To compensate for the challenge, the SOs visit the mortuaries within health facilities to trace and report cases of cancer for patients who may have been missed while alive.

Figure 3 below illustrates the spatial distribution of the data sources for EPBCR as of 31 December 2020.




Figure 1: Ekurhuleni Population-based cancer registry data sources map, 31 December 2020

Data collection and processes

The EPBCR uses both active and passive methods of case finding.

Active case finding:

- The surveillance officers visit healthcare facilities to review electronic and or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinician's statistical records to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

- As mentioned above, both the South African Paediatric Oncology Research Group and the South African Oncology Consortium (SAOC) passively provide data to the NCR for the Ekurhuleni district.

Inclusion criteria for both active and passive case finding methods:

- All confirmed cancer cases, in persons who are resident in the Ekurhuleni metropolitan municipality, diagnosed from 1st January to 31 December of the relevant year must be reported to the registry.
- Cancer cases include:
 - Cases considered malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behaviour code-3 are reported to the registry.
 - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumour site topography. If this is not known, it is registered as an unknown primary site.

The surveillance officers extract data/variables required (See Appendix 2: South African Cancer Registration Form) from data sources such as medical records and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3rd edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then sent to data capturers for data entry on the RedCap system. The NCR uses RedCap instead of the IARC recommended CanReg system because CanReg did not meet the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.

The captured files are sent to the surveillance manager for quality assurance and quality control. The surveillance manager uses both the physical notification forms and electronic records on Redcap for each cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years as per the South Africa Protection of Personal Information Act (POPI Act) before they are permanently destroyed (10). The completed, quality assured dataset is extracted per year (1st January to 31st December for each year) for cleaning and analysis using Stata software. The analyzed data is then used for annual incidence reports, teaching/training, and research purposes. Figure 2, below illustrates the data processing and flow for the EPBCR.

Figure 4: EPBCR data flow




Figure 2: Ekurhuleni Population Based Cancer Registry data flow diagram

Confidentiality

The NCR adheres to the NHLS, the IARC/IACR guidelines and the POPI Act to ensure the preservation of privacy during the EPBCR surveillance process (10). Request to use de-identified individual-level EPBCR data by entities/individuals is sought in writing to the NCR. Ethics approval is required before data is granted. The statistics of cancer data are released in an aggregated format through the annual reports published on the NCR website.

Statistical analysis

The results are presented as:

- the number of new cancer cases,
- the percentage of all new cancer cases,
- Age-standardised incidence rate (ASR) per 100,000 and
- The lifetime risk

The results are further stratified by:

- sex (Male and Female),
- population group (Black, White, Asian and Coloured) and
- age groups (5-year interval, e.g. 0-5 years, 5-10, 10-15, etc.).

For age standardization, the Segi World Standard Population (WSP) is used as per international cancer registration norms. STATS SA mid-year population data for Ekurhuleni metropolitan municipality is used as a denominator.

The calculation methods are as follows:

$$\text{Crude} = \frac{\text{Number of new cases}}{\text{Mid-year population}} \times 100,000$$

$$\text{WSP weighting} = \frac{\text{WSP (for each age group)}}{\text{Total WSP for all age groups}} \times 100,000$$

$$\text{ASR} = \text{Crude} \times \text{WSP weighting}$$

RESULTS

Overall cancer incidence

A total of 3130 cancer cases were registered by the EPBCR for the year 2020 with 1508 cases (48.2%) occurring in males and 1623 (51.8%) occurring in females. Benign, in-situ cancers and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 3 below shows the percentage of cancer cases diagnosed in 2020 by gender and race. Fifty-two per cent of cases were diagnosed among the White population, 45% among the Black population, while 2% and 1% was diagnosed among the Coloured and Asian population groups, respectively.




Figure 3: Percentage of cancer cases by gender and race.

Tables 1 and 2 illustrate a detailed tabulation of cases registered in 2020 for males and females. The tables show the total number of cases registered, crude rates per 100 000 population, age-adjusted incidence rates per 100 000 population, and lifetime risk for each cancer. Appendix tables further elaborate on these data by demonstrating frequency, age-standardised and age-specific incidence rates by population group and gender.

Table 1: Summary statistics for all cancers in Men, Ekurhuleni (2020)

SITE	ICD10	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites but C44	All	1509	64,72	66,28	8	13
All sites	All but C44	1063	91,88	94,08	11	9
Prostate	C61	406	24,72	26,37	4	28
BCC	C44	320	19,48	20,03	2	44
SCC of skin	C44	114	6,94	7,02	1	129
Primary site unknown	C80	85	5,11	5,19	1	163
Colorectal	C18	78	4,75	4,81	1	171
Bladder	C67	61	3,71	3,87	0	213
Lung	C34	43	2,62	2,73	0	321
Oesophagus	C15	39	2,37	2,53	0	312
Melanoma	C43	34	2,07	2,03	0	446
Non-Hodgkin lymphoma	C84	34	2,07	1,97	0	458
Kaposi Sarcoma	C46	30	1,83	1,53	0	722
Pancreas	C25	21	1,28	1,31	0	543
Larynx	C32	21	1,28	1,41	0	539
Liver & Bile duct	C22	18	1,10	1,05	0	842
Kidney	C64	16	0,97	1,01	0	836
Stomach	C16	14	0,85	0,73	0	1509
Other specified	C63	14	0,85	0,82	0	887
Skin other	C44	12	0,73	0,76	0	1172
Testis	C62	12	0,73	0,58	0	2084
Tongue	C02	11	0,67	0,74	0	1133
Anus	C21	11	0,67	0,62	0	1456
Brain, CNS	C71	11	0,67	0,69	0	1991
Myeloma	C90	11	0,67	0,71	0	1293
Leukaemia	C92	11	0,67	0,61	0	1676
Hodgkin lymphoma	C81	10	0,61	0,54	0	2345
Mouth	C06	9	0,55	0,54	0	1587
Naso-Oropharynx	C11	8	0,49	0,54	0	1590
Breast	C50	8	0,49	0,48	0	1822
Connective tissue	C49	7	0,43	0,45	0	2451
Penis	C60	7	0,43	0,41	0	2058
Eye	C69	7	0,43	0,41	0	3185
Endocrine	C74	5	0,30	0,28	0	2858
Ill defined	C76	5	0,30	0,30	0	2294
Bone	C41	4	0,24	0,24	0	5525
Mesothelioma	C45	3	0,18	0,19	0	3096
Lip	C00	2	0,12	0,12	0	7693
Salivary gland	C07	2	0,12	0,12	0	6826
Thyroid	C73	2	0,12	0,10	0	12270
Gum	C03	1	0,06	0,07	0	9133
Small intestine	C17	1	0,06	0,06	0	20203
Haematology other	C96	1	0,06	0,06	0	16130

*N** includes cases with unknown age

Table 2: Summary statistics for all cancers in Women, Ekurhuleni (2020)

SITE	ICD10	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	All	1622	93,39	99,13	10	10
All sites but C44	All but C44	1374	79,11	81,63	9	12
Cervix	C53	406	23,38	21,71	2	47
Breast	C50	331	19,06	19,76	2	44
BCC	C44	187	10,77	13,06	1	75
Primary site unknown	C80	114	6,56	7,59	1	126
Colorectal	C18	59	3,40	3,52	1	197
Uterus	C54	58	3,34	3,88	0	222
SCC of skin	C44	55	3,17	4,08	0	271
Ovary	C56	37	2,13	2,05	0	428
Melanoma	C43	34	1,96	2,23	0	391
Lung	C34	29	1,67	2,19	0	356
Other specified	C63	28	1,61	1,69	0	618
Non-Hodgkin lymphoma	C84	27	1,55	1,66	0	655
Oesophagus	C15	21	1,21	1,51	0	774
Vulva	C51	19	1,09	0,96	0	1037
Bladder	C67	19	1,09	1,38	0	593
Liver & Bile duct	C22	17	0,98	1,20	0	1221
Pancreas	C25	16	0,92	1,07	0	794
Thyroid	C73	16	0,92	0,93	0	1368
Stomach	C16	15	0,86	0,95	0	897
Kaposi Sarcoma	C46	14	0,81	0,73	0	1877
Myeloma	C90	14	0,81	0,80	0	1058
Hodgkin lymphoma	C81	11	0,63	0,62	0	1666
Anus	C21	9	0,52	0,54	0	1264
Brain, CNS	C71	9	0,52	0,50	0	1969
Leukaemia	C92	8	0,46	0,58	0	2007
Vagina	C52	7	0,40	0,37	0	2003
Salivary gland	C07	6	0,35	0,25	0	4292
Naso-Oropharynx	C11	6	0,35	0,33	0	3049
Skin other	C44	6	0,35	0,36	0	1969
Eye	C69	6	0,35	0,34	0	2946
Kidney	C64	5	0,29	0,33	0	3884
III defined	C76	5	0,29	0,27	0	3598
Tongue	C02	4	0,23	0,29	0	2351
Mouth	C06	4	0,23	0,22	0	4082

Small intestine	C17	4	0,23	0,21	0	5264
Mesothelioma	C45	4	0,23	0,27	0	1859
Bone	C41	3	0,17	0,15	0	10696
Connective tissue	C49	3	0,17	0,19	0	9434
Larynx	C32	2	0,12	0,14	0	3491
Endocrine	C74	2	0,12	0,11	0	8929
Placenta	C58	1	0,06	0,06	0	13699
Haematology other	C96	1	0,06	0,06	0	13699

N* includes cases with unknown age

Figure 4-7 below illustrates the frequency and age-standardised incidence rates of the most common cancers registered in the EPBCR in 2020 for males and females. Prostate cancer was by far the commonest cancer amongst men with 406 cases and an ASR of 26,37/100 000 population. Amongst women, cervical cancer was leading with 406 new cases reported with an ASR of 21,71/100 000. Figure 8 and 9 illustrate the top 5 cancers ASRs by population group. The White population had the highest ASR, followed by Black, Coloured and Asian populations respectively.




Figure 4: Frequency of most common cancers in males

ASR for most common cancers in men, 2020




Figure 5: Age Standardised Incidence Rates for common cancers in males

*Only cases with known ages included

Top 10 most common cancers among women, 2020




Figure 6: Frequency of top 10 common cancers in females

ASR for most common cancers in women, 2020




Figure 7: Age standardised incidence rates for the common cancers in females

*Only cases with known ages included

Top 5 most common cancers in men by population group: 2020

■ Coloured ■ Asian ■ Black ■ White




Figure 8: ASR of common cancers in men by population group

Top 5 most common cancers in women by population group: 2020




Figure 8: ASR of common cancers in women by population group

Comparison with year 2017, 2018, 2019 & 2020

Figure 10 and 11 show a comparison of reported cancer cases from 2017 to 2020 by gender. There was a 23% increase in the number of cancer cases reported in 2020 (n=3131) vs the year 2019 (n=2541). Among males, there was a 43% increase from 1052 in 2019 while among females there was a 9% increase from 1489 in 2020. The pattern of the most common top 5 cancers age-standardised incidence rates by sex remained the same between 2017 and 2020 with few exceptions for males where oesophagus cancer replaced lung from top 3 to top 4 in 2019. Whereas in 2020 bladder cancer and oesophagus cancer among males replaced lung cancer (from top 3 to top 4) and non-Hodgkin lymphoma (from top 4 to top 6).

ASR of the most common cancers in men: 2017-2020




Figure 9: Age standardised incidence rates of the most common cancers in men, 2017-2020

ASR of the most common cancers in women: 2017-2020




Figure 10: Age standardised incidence rates of the most common cancers in women, 2017-2020

Number of cancer cases reported by EPBCR: 2017-2020




Figure 11: Number of Cancer cases reported by year and gender

Childhood cancer incidence

Table 3 below shows the top 10 cancers in children aged 0-14 years in the Ekurhuleni area. Twenty cancers were registered in 2020 among children. Paediatric cancers accounted for 1.1% of all cancers registered in 2020. There were more cancers in boys than girls. Leukaemias, CNS neoplasms and lymphomas were the most common cancers in children.

Table 3: Childhood cancers 2020

Cancer	Number of cases					Rates per Million Age-Specific Rates						
	Age 0-4	Age 5-9	Age 10-14	All Ages	M/F ratio	Age 0-4	Age 5-9	Age 10-14	Crude	ASR	LCL	UCL
Leukaemia	1	1	1	3	0	3	4	4	3,91	3,90	0,80	11,41
Lymphoma	0	1	1	2	1	0	4	4	2,61	2,55	0,31	9,28
CNS Neoplasms	1	0	2	3	2	3	0	9	3,91	3,91	0,80	11,41
Neuroblastoma	0	0	0	0	0	0	0	0	0,00	0,00	0,00	4,80
Retinoblastoma	0	1	0	1	0	0	4	0	1,30	1,28	0,03	7,18
Nephroblastoma - Wilms Tumour	1	1	0	2	1	3	4	0	2,61	2,63	0,32	9,46
Bone Tumours	0	0	0	0	0	0	0	0	0,00	0,00	0,00	4,80
Soft Tissue Sarcomas	0	0	0	0	0	0	0	0	0,00	0,00	0,00	4,80
Germ Cell Tumours	0	0	0	0	0	0	0	0	0,00	0,00	0,00	4,80
Primary site unknown	0	0	0	0	0	0	0	0	0,00	0,00	0,00	4,80
Other, specified	3	3	3	9	2	10	12	13	11,74	11,71	5,35	22,23
Total	6	7	7	20		21	28	31	26	26	8	95

Data Quality Indicators

a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases that were morphologically verified (MV) using histology, cytology or bone marrow aspirate and trephine, diagnosed by clinical means or registered from death certificate-only information (DCO).

Table 4: Percentage of cases Morphologically Verified, diagnosed clinically or diagnosed by Death Certificate Only

ICD 10 Cancer Site	No. of Cases	(% Total)	Basis of Diagnosis		
			DCO	Clinical	MV
C00 Lip	2.0	0.1	0.0	0.0	100.0
C02 Tongue	15.0	0.5	0.0	6.7	93.3
C03 Gum	1.0	0.0	0.0	0.0	100.0
C06 Mouth	13.0	0.4	0.0	0.0	100.0
C07 Salivary gland	8.0	0.3	0.0	25.0	75.0
C11 Naso-Oropharynx	14.0	0.4	0.0	0.0	100.0
C15 Oesophagus	60.0	1.9	5.0	20.0	75.0
C16 Stomach	29.0	0.9	0.0	13.8	86.2
C17 Small intestine	5.0	0.2	0.0	0.0	100.0
C18-20 Colorectal	137.0	4.4	2.2	8.8	89.1
C21 Anus	20.0	0.6	0.0	15.0	85.0
C22 Liver & Bile duct	35.0	1.1	2.9	25.7	71.4
C25 Pancreas	37.0	1.2	5.4	35.1	59.5
C26,C38,C48,C57,C58,C63,C68 Other specified	43.0	1.3	2.4	11.9	85.7
C32 Larynx	23.0	0.7	0.0	13.0	87.0
C34 Lung	72.0	2.3	5.6	15.3	79.2
C41 Bone	7.0	0.2	0.0	42.9	57.1
C43 Melanoma	68.0	2.2	0.0	2.9	92.6
C44 BCC	507.0	16.2	0.0	0.4	98.8
C44 SCC of skin	169.0	5.4	0.0	0.0	99.4
C44 Skin other	18.0	0.6	0.0	11.1	88.9
C45 Mesothelioma	7.0	0.2	0.0	0.0	100.0
C46 Kaposi Sarcoma	44.0	1.4	0.0	9.1	90.9
C49 Connective tissue	10.0	0.3	0.0	20.0	70.0
C50 Breast	339.0	10.8	1.5	3.8	94.7
C51 Vulva	19.0	0.6	0.0	0.0	100.0
C52 Vagina	7.0	0.2	0.0	14.3	85.7
C53 Cervix	406.0	13.0	0.5	6.9	92.4
C54 Uterus	58.0	1.9	0.0	5.2	93.1
C60 Penis	7.0	0.2	0.0	14.3	85.7
C61 Prostate	406.0	13.0	0.7	3.7	95.6
C62 Testis	12.0	0.4	0.0	0.0	100.0
C64 Kidney	21.0	0.7	0.0	19.0	81.0

C67 Bladder	80.0	2.6	1.3	5.0	93.8
C69 Eye	13.0	0.4	0.0	7.7	92.3
C71 Brain, CNS	20.0	0.6	0.0	25.0	75.0
C73 Thyroid	18.0	0.6	5.6	5.6	88.9
C74 Endocrine	7.0	0.2	0.0	14.3	85.7
C76 Ill defined	10.0	0.3	0.0	20.0	80.0
C80 Ovary	38.0	1.2	0.0	36.8	63.2
C80 Primary site unknown	198.0	6.3	4.6	23.9	71.6
C81 Hodgkin lymphoma	21.0	0.7	4.8	4.8	90.5
C85 Non-Hodgkin lymphoma	61.0	1.9	0.0	14.8	83.6
C90 Myeloma	25.0	0.8	0.0	16.0	84.0
C92 Leukaemia	19.0	0.6	0.0	42.1	52.6
C96 Haematology other	2.0	0.1	0.0	0.0	100.0
Total	3,131.0	100.0	1.2	8.1	90.4

b) Primary site unknown (PSU)

There were 198 cases of cancer (6.3%) reported where the primary site was unspecified or uncertain from the available documentation. The rates of PSU were 5.19 and 7.59 /100 000 in men and women respectively.

c) Age unknown

There was only one record with unknown age, and it was amongst males.

DISCUSSION

This report covers the fourth year of EPBCR data reporting since 2017. The data presented, reports cancer cases that were diagnosed among residents of Ekurhuleni metropolitan municipality in Gauteng province of South Africa between 1 January and 31 December 2020. Data collection for 2020 cancer cases was conducted in the year 2020/2021 and the database was closed in October 2021. In cancer surveillance, data are always collected retrospectively due to the long turnaround time for diagnosis with a universal standard of a two-year lag, hence the collection of 2020 EPBCR data in 2020 and 2021.

Overall, there were 3131 cases reported by the EPBCR for the year 2020, which is a 23% increase from the year 2019 (2541), however, it is a 33% decrease from the year 2018 (n=4695). The year 2020 has been one of the most challenging years for public health surveillance globally. The percentage changes indicating a decrease in data collection for 2019 and 2020 may be attributed to numerous challenges including but not limited to: i) the COVID-19 pandemic, ii) Charlotte Maxeke Johannesburg Academic Hospital catastrophe (Fire disaster, 16 April 2021) and iii) misinterpretation of the POPI Act which was implemented in July 2020.

The South African COVID-19 epidemic which started in March 2020, and the consequent lockdown resulted in restricted access for EPBCR surveillance officers to collect cancer data in health facilities. Some wards within hospitals were closed due to healthcare workers having contracted COVID-19, outpatient clinics were non-operational for elective appointments and surveillance officers were temporarily barred from general wards as their movements were regarded as posing an infectious risk. In addition, under-diagnosis of cancer cases emanating from lockdown restrictions, limited patient movement, health facilities prioritising COVID-19 patients, patients' anxiety to visit hospitals for early diagnosis, suspension of elective surgery lists with consequent delays in cancer diagnoses may have affected the cancer incidence reporting for 2020. The NCR also seconded five key staff members to the NICD COVID response team for several months, leaving a gap in cancer surveillance activities.

On 16 April 2021, Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) caught fire resulting in the loss of patient files and was closed and surveillance officers were not able to conduct cancer surveillance activities. The CMJAH alone contributes 23% of EPBCR cases on average.

On the 1st of July 2020, the Protection of Personal Information Act (POPIA) came into effect and that resulted in several private sector data sources withholding cancer data from the surveillance officers. Engagement with stakeholders/data custodians was held and the majority of the health facilities reopened doors for the surveillance officers to conduct cancer surveillance, apart from an estimated 2%, where the engagement was still ongoing at the time of drafting this report. Despite the challenges encountered by the EPBCR surveillance officers in collecting data for cancers that were diagnosed in 2020, this report provides valuable information on overall cancer patterns in Ekurhuleni district.

The frequency and age-standardised incidence rates analysis of 2020 EPBCR has shown that the most common cancers among males were prostate, colorectal and bladder, whereas among women the most common cancers were cervix, breast, and colorectal respectively. The frequency of cancers is useful for determining the burden on the country's health care system for screening, diagnosis, treatment and care of cancer patients. On the other hand, the age-standardised incidence rates are used to compare rates of cancer between the different geographic regions and populations.

The general pattern of cancer among men and women remains similar to previous years with a few exceptions such as bladder cancer and oesophagus reported in the top five cancers among men. These patterns are almost similar to those of the 2020 GLOBOCAN estimates where bladder cancer is ranked 5th while oesophagus cancer is ranked 6th among the top ten common cancers in men (11).

Among children (0-14 years) there were 20 cases registered for 2020. Leukaemia was the most common cancer in children. The percentage of morphologically verified cancer cases ranged from 57.1 % to 100%.

In the 2022/23 financial year, the NCR will continue to strengthen the EPBCR system and set a benchmark for the other planned population-based cancer registries in SA in an effort to gather comprehensive, representative and best quality cancer data to inform cancer prevention and control in the country.

EPBCR will focus on real-time 2022 data collection (abstraction of cancer cases data as they get diagnosed), as well as consolidation of the years 2020 and 2021 in order to correct for the underreporting due to the challenges encountered during the COVID-19 pandemic.

The main priorities i) will be to submit the EPBCR (2017-2020) data to IARC, ii) to produce the 2021 EPBCR annual report, iii) to enhance the engagement to implement PBCR in KwaZulu-Natal province and iv) to increase data sources in order to optimise case finding.

CONCLUSION

Population-based cancer registration is the key for countries to effectively drive cancer policy, decision making, and intervention programmes which are aimed at reducing cancer cases and deaths. The Ekurhuleni population-based cancer registry has progressively produced four years of quality cancer data for South Africa. Regardless of the challenges encountered such as the COVID-19 pandemic, POPIA and the Charlotte Maxeke Johannesburg Academic Hospital fire, the results of the 2020 EPBCR reports are significant. Overall, the pattern of cancers reported in the year 2020 are similar to that of other countries in the globe as well as the past years of reporting since 2017. The most common cancers registered were prostate, colorectal and bladder cancers among males and cervix, breast, and colorectal cancer among females. Among children (0-14 years) the most common cancers were leukaemia, lymphoma and CNS Neoplasms, respectively. The EPBCR has set a benchmark for an implementation of the future PBCR in SA.

ACKNOWLEDGEMENTS

This work has been possible through seed funding provided by the South African Medical Research Council. The NCR would also like to thank the National Institute for Communicable Diseases for the continuous support in indirect costs for EPBCR. We would like to thank the National Department of Health for additional funding that has assisted in the continued operations of the EPBCR.

The National Cancer Registry (NCR) would also like to thank all individuals, organisations and relevant stakeholders that played a critical role in the operations of the Ekurhuleni Population-Based Cancer Registry.

African Cancer Registry Network (AFCRN)

Tambo Memorial Regional Hospital

Tembisa Regional Hospital

Steve Biko Academic Hospital

Thelle Mogoerane Regional Hospital

Union for International Cancer Control (UICC)

Vermaak Laboratories

World Health Organization (WHO)

South African Medical Research Council (SAMRC)

Ampath Laboratories

Arebaoke Hospice

Benoni Oncology Centre

Chris Hani Baragwanath Academic Hospital

Charlotte Maxeke Academic Hospital

Drs Gritzman & Thatcher Inc Laboratories

Eastrand Benoni Hospice

Edenvale Regional Hospital

Far East Regional Hospital

Gauteng Oncology Alberton Private Hospital

Gauteng Oncology Prostate-Clinic

Gauteng Oncology Linmed Private Hospital

International Agency for Research on Cancer (IARC)

International Association of Cancer Registries (IACR)

Lancet Laboratories

National Department of Health South Africa

National Health Laboratory Services

National Institute for Communicable Diseases

Pathcare Laboratories

Pholosong Regional Hospital

South African Oncology Consortium (SAOC)

South African Paediatric Oncology Network

St Francis Hospice

Stepping Stone Hospice

REFERENCES

1. C P Wild, E Weiderpass BWS (editors). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. Available [Internet]. Vol. 199, Cancer Control. 2020. 512 p. Available from: <http://publications.iarc.fr/586>
2. ICCP. Cancer Registries ICCP Portal [Internet]. ICCP. 2019 [cited 2020 Nov 19]. Available from: <https://www.iccp-portal.org/cancer-registries>
3. WHO. Cancer key facts [Internet]. 2020 [cited 2020 Nov 19]. Available from: <https://www.who.int/news-room/fact-sheets/detail/cancer>
4. Assembly UNG. Resolution A/RES/65/238: Scope, modalities, format and organization of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 2011;11759(April):1–4.
5. IARC. The role and status of population-based cancer registration. 2007;X.
6. IARC. About the GICR [Internet]. 2011 [cited 2021 Mar 29]. Available from: <https://gicr.iarc.fr/about-the-gicr/>
7. Omonisi AE, Liu B, Parkin DM. Population-Based Cancer Registration in Sub-Saharan Africa: Its Role in Research and Cancer Control. JCO Glob Oncol [Internet]. 2020 Nov 12 [cited 2021 Mar 29];(6):1721–8. Available from: <https://ascopubs.org/doi/10.1200/GO.20.00294>
8. KwaZulu-Natal Department of Health. Referral system: levels of care [Internet]. 2014 [cited 2019 Feb 19]. p. 2017. Available from: <http://www.kznhealth.gov.za/Referral-system.htm>
9. NHLS. 2017/18 NHLS Annual Report [Internet]. Sandringham; 2018. Available from: http://www.nhls.ac.za/assets/files/an_report/NHLS_AR_2018.pdf
10. Parliament of the Republic of south Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013 [cited 2019 Mar 27];(4):154. Available from: <http://www.justice.gov.za/inforeg/docs/InfoRegSA-POPIA-act2013-004.pdf>
11. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global

Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May 1 [cited 2022 Mar 30];71(3):209–49. Available from: <https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21660>

APPENDICES

Appendix 1: List of Data Sources

PUBLIC HOSPITALS

- ❖ Charlotte Maxeke Johannesburg Academic Hospital
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Tshwane District Hospital
- ❖ Pholosong Regional Hospital
- ❖ Far East Rand Regional Hospital
- ❖ Thelle Mogoerane Regional Hospital
- ❖ Tembisa Regional Hospital
- ❖ Tambo Memorial Regional Hospital
- ❖ Edenvale Hospital

PRIVATE HEALTH FACILITIES

- ❖ Benoni Oncology Centre
- ❖ Gauteng Prostate Oncology - Morehill Clinic
- ❖ Gauteng Oncology - Benoni Oncology Centre
- ❖ Gauteng Oncology - Linmed Hospital
- ❖ Netcare Clinton Oncology
- ❖ Independent Practitioners

HOSPICES

- ❖ East Rand Hospice
- ❖ Flora Madiba Hospice
- ❖ Stepping Stone Hospice
- ❖ St Francis Hospice

SOUTH AFRICAN ONCOLOGY CONSORTIUM

- ❖ Private Oncologists

PAEDIATRIC ONCOLOGY

- ❖ CHOC Childhood cancer foundation
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Donald Gordon Medical Oncology Unit

NHLS

- ❖ CDW pathology based cancer reports

Appendix 2: South African Cancer Notification Form

 health Department: Health REPUBLIC OF SOUTH AFRICA <small>National Health Act, 2003 (Act No. 61 of 2003) Regulation Number 380</small>	Republic of South Africa Department of Health CANCER REGISTRATION FORM	<small>To be completed in duplicate in BLOCK LETTERS. Please mark with <input checked="" type="checkbox"/> the CORRECT box, where required. Original to be submitted to the National Cancer Register and copy to be retained: To be submitted to the National Cancer Register via: e-mail: cancer.registry@nhls.ac.za fax: 011 489 9132 / 011 489 9152 Post: PO Box 1038, Johannesburg, 2000</small>
A. PARTICULARS OF INDIVIDUAL		
1. Name of facility <input type="text"/>		
USE PATIENT STICKER <i>if available</i>		
2. Surname <input type="text"/>		
3. Full names <input type="text"/>		
4. Date of birth <input type="text"/>		
5. Folder number <input type="text"/>		
6. Sex <input type="checkbox"/> Male <input type="checkbox"/> Female		
7. ID number/Passport number <input type="text"/>		
8. Race group <input type="checkbox"/> African <input type="checkbox"/> Coloured <input type="checkbox"/> White <input type="checkbox"/> Indian <input type="checkbox"/> Other _____		
9. Area of residence 9.1 City/town/village <input type="text"/> 9.2 Postal code <input type="text"/> 9.3 How long at this address? <input type="text"/> years		
Please record place of birth if not the same as current address		
9.4 City/town/village <input type="text"/> 9.5 Postal code <input type="text"/>		
B. RISK FACTOR PROFILE		
10. Usual occupation of patient <input type="text"/> <small>(If retired, give type of work done for most of working life)</small>		
11. Type of industry/business <input type="text"/> <small>(eg Mining, farming etc)</small>		
12. Did the patient ever smoke tobacco? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown		
13. Did the patient ever consume alcohol regularly? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <small>(that is, more than once a week)</small>		
14. HIV status <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Unknown		
C. CLINICAL AND LABORATORY DETAILS		
15. Date of diagnosis <input type="text"/>		
16. Cancer diagnosis and Histology <small>Please give all information available on the site, laterality, histology and behaviour of the tumour</small> <hr/> <hr/>		
17. ICD-10 <input type="text"/> • <input type="checkbox"/>		
18. Grade <input type="checkbox"/> Well differentiated <input type="checkbox"/> Moderately differentiated <input type="checkbox"/> Poorly differentiated <input type="checkbox"/> Unknown/Not applicable		
19. Stage <input type="checkbox"/> Primary/localised <input type="checkbox"/> Metastatic <input type="checkbox"/> Unknown/Not applicable		
20. Invasiveness <input type="checkbox"/> In-situ <input type="checkbox"/> Invasive		
21. Basis of diagnosis <input type="checkbox"/> Clinical <input type="checkbox"/> Clinical with investigation <input type="checkbox"/> Cytology/histopathology <input type="checkbox"/> Molecular <input type="checkbox"/> Death Certificate		
22. Prescribed treatment <input type="checkbox"/> Surgery <input type="checkbox"/> Radiation <input type="checkbox"/> Chemotherapy <input type="checkbox"/> Other <input type="checkbox"/> Palliation <input type="checkbox"/> Alternative <input type="checkbox"/> None		
INFORMANT PARTICULARS		OFFICE CODING
Name (Print) _____		<input type="text"/> • <input type="checkbox"/>
MP/NC Number <input type="text"/>		M - <input type="text"/> / <input type="checkbox"/> / <input type="checkbox"/>
Signature _____		Date _____

Appendix 3: Tables of Incidence by site, sex, age group and population

Tables of ASR and Crude Incidence by population group

Asian Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Breast	4	33,33	4	12,36	13,09	3,50	34,57
Uterus	3	25,00	3	9,27	11,53	2,31	33,58
Primary site unknown	2	16,67	2	6,18	6,51	0,71	24,99
III defined	1	8,33	1	3,09	4,47	0,11	22,93
Myeloma	1	8,33	1	3,09	3,36	0,09	19,80
Cervix	1	8,33	1	3,09	1,97	0,05	16,53

Black Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Cervix	361	40,47	361	27,11	28,00	25,06	31,19
Breast	183	20,52	183	13,74	15,00	12,82	17,45
Primary site unknown	59	6,61	59	4,43	5,39	4,06	7,02
Uterus	40	4,48	40	3,00	3,86	2,73	5,29
Colorectal	21	2,35	21	1,58	1,65	0,99	2,59
Ovary	20	2,24	20	1,50	1,48	0,88	2,34
Non Hodgkin lymphoma	19	2,13	19	1,43	1,53	0,89	2,45
Oesophagus	18	2,02	18	1,35	1,85	1,08	2,93
Vulva	16	1,79	16	1,20	1,08	0,60	1,82
Other specified	15	1,68	15	1,13	1,04	0,57	1,78
Kaposi Sarcoma	13	1,46	13	0,98	0,82	0,43	1,47
Hodgkin lymphoma	9	1,01	9	0,68	0,67	0,30	1,32
Liver & Bile duct	8	0,90	8	0,60	0,77	0,32	1,52
Myeloma	8	0,90	8	0,60	0,60	0,25	1,23
Pancreas	7	0,78	7	0,53	0,68	0,27	1,40
Melanoma	7	0,78	7	0,53	0,65	0,25	1,36
Stomach	7	0,78	7	0,53	0,60	0,23	1,28
BCC	7	0,78	7	0,53	0,48	0,18	1,06
SCC of skin	7	0,78	7	0,53	0,48	0,18	1,06
Lung	6	0,67	6	0,45	0,61	0,22	1,34
Leukaemia	5	0,56	5	0,38	0,42	0,14	1,01
Bladder	5	0,56	5	0,38	0,40	0,12	0,99
Vagina	5	0,56	5	0,38	0,40	0,12	0,97
Eye	5	0,56	5	0,38	0,38	0,12	0,93
Thyroid	5	0,56	5	0,38	0,38	0,11	0,96
Anus	5	0,56	5	0,38	0,37	0,11	0,94
Small intestine	4	0,45	4	0,30	0,30	0,08	0,81
Brain, CNS	4	0,45	4	0,30	0,28	0,07	0,77
Salivary gland	4	0,45	4	0,30	0,25	0,07	0,73
Naso-Oropharynx	3	0,34	3	0,23	0,25	0,04	0,77
Bone	3	0,34	3	0,23	0,18	0,04	0,61
Tongue	2	0,22	2	0,15	0,22	0,03	0,76
Kidney	2	0,22	2	0,15	0,21	0,03	0,74
Ill defined	2	0,22	2	0,15	0,16	0,02	0,63
Connective tissue	2	0,22	2	0,15	0,15	0,02	0,58
Skin other	2	0,22	2	0,15	0,15	0,02	0,58
Mouth	2	0,22	2	0,15	0,13	0,01	0,55
Endocrine	1	0,11	1	0,08	0,08	0,00	0,49

Coloured Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	9	42,86	9	20,18	17,43	7,69	34,55
Cervix	4	19,05	4	8,97	9,23	2,35	24,41
Liver & Bile duct	2	9,52	2	4,48	4,52	0,52	16,97
BCC	1	4,76	1	2,24	2,59	0,07	14,13
Tongue	1	4,76	1	2,24	1,90	0,05	12,31
Uterus	1	4,76	1	2,24	1,86	0,05	12,20
Brain, CNS	1	4,76	1	2,24	1,67	0,04	11,74
Vulva	1	4,76	1	2,24	1,67	0,04	11,74
Salivary gland	1	4,76	1	2,24	1,33	0,03	11,00

White Females: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
BCC	179	25,68	179	76,62	40,04	33,82	47,29
Breast	135	19,37	135	57,78	32,17	26,61	38,76
Primary site unknown	53	7,60	53	22,69	13,10	9,29	18,11
SCC of skin	48	6,89	48	20,55	8,66	6,21	12,14
Cervix	40	5,74	40	17,12	11,61	8,17	16,22
Colorectal	38	5,45	38	16,26	8,14	5,64	11,72
Melanoma	27	3,87	27	11,56	6,26	4,02	9,62
Lung	23	3,30	23	9,84	4,37	2,70	7,16
Ovary	17	2,44	17	7,28	4,51	2,54	7,71
Uterus	14	2,01	14	5,99	3,21	1,69	5,94
Bladder	14	2,01	14	5,99	3,20	1,68	5,93
Other specified	13	1,87	13	5,56	3,00	1,51	5,72
Thyroid	11	1,58	11	4,71	3,51	1,61	6,80
Pancreas	9	1,29	9	3,85	1,52	0,62	3,71
Non Hodgkin lymphoma	8	1,15	8	3,42	1,99	0,74	4,62
Stomach	8	1,15	8	3,42	1,59	0,62	3,86
Liver & Bile duct	7	1,00	7	3,00	1,44	0,50	3,73
Myeloma	5	0,72	5	2,14	1,13	0,32	3,34
Brain, CNS	4	0,57	4	1,71	1,73	0,35	4,85
Skin other	4	0,57	4	1,71	0,91	0,23	3,01
Anus	4	0,57	4	1,71	0,77	0,19	2,79
Mesothelioma	4	0,57	4	1,71	0,75	0,20	2,73
Naso-Oropharynx	3	0,43	3	1,28	1,47	0,26	4,41
Kidney	3	0,43	3	1,28	0,67	0,12	2,73
Oesophagus	3	0,43	3	1,28	0,52	0,10	2,44
Leukaemia	3	0,43	3	1,28	0,46	0,09	2,34
Ill defined	2	0,29	2	0,86	0,78	0,09	3,08
Mouth	2	0,29	2	0,86	0,61	0,07	2,70
Vagina	2	0,29	2	0,86	0,56	0,05	2,67
Hodgkin lymphoma	2	0,29	2	0,86	0,56	0,05	2,67
Vulva	2	0,29	2	0,86	0,35	0,03	2,25
Larynx	2	0,29	2	0,86	0,34	0,04	2,22
Salivary gland	1	0,14	1	0,43	0,32	0,01	2,31
Endocrine	1	0,14	1	0,43	0,31	0,01	2,30
Eye	1	0,14	1	0,43	0,28	0,01	2,23
Haematology other	1	0,14	1	0,43	0,24	0,01	2,15
Placenta	1	0,14	1	0,43	0,24	0,01	2,15
Tongue	1	0,14	1	0,43	0,17	0,00	2,03
Kaposi Sarcoma	1	0,14	1	0,43	0,15	0,00	2,00
Connective tissue	1	0,14	1	0,43	0,11	0,00	1,95

Asian Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Lung	5	26,32	5	14,28	21,65	6,51	52,88
Primary site unknown	3	15,79	3	8,57	8,20	1,51	30,46
Colorectal	2	10,53	2	5,71	7,96	0,96	31,60
Prostate	2	10,53	2	5,71	6,48	0,76	28,53
Testis	2	10,53	2	5,71	4,47	0,48	24,80
Bladder	1	5,26	1	2,86	3,72	0,09	25,05
Larynx	1	5,26	1	2,86	3,53	0,09	24,60
Other specified	1	5,26	1	2,86	2,87	0,07	23,18
BCC	1	5,26	1	2,86	2,76	0,07	22,97
Tongue	1	5,26	1	2,86	2,27	0,06	22,06

Black Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	201	38,07	201	14,05	23,30	20,07	26,86
Primary site unknown	42	7,95	42	2,94	3,70	2,61	5,11
Oesophagus	27	5,11	27	1,89	2,77	1,79	4,09
Kaposi Sarcoma	26	4,92	26	1,82	1,42	0,92	2,18
Colorectal	24	4,55	24	1,68	2,11	1,33	3,20
Non Hodgkin lymphoma	22	4,17	22	1,54	1,56	0,93	2,48
Lung	15	2,84	15	1,05	1,31	0,71	2,24
Larynx	12	2,27	12	0,84	1,02	0,52	1,84
Liver & Bile duct	10	1,89	10	0,70	0,76	0,34	1,51
Leukaemia	10	1,89	10	0,70	0,65	0,29	1,30
Hodgkin lymphoma	10	1,89	10	0,70	0,60	0,28	1,20
Bladder	9	1,70	9	0,63	0,81	0,37	1,58
Pancreas	9	1,70	9	0,63	0,76	0,32	1,55
Mouth	9	1,70	9	0,63	0,74	0,32	1,47
SCC of skin	8	1,52	8	0,56	0,88	0,35	1,80
Anus	8	1,52	8	0,56	0,59	0,24	1,27
BCC	7	1,33	7	0,49	0,73	0,25	1,58
Breast	7	1,33	7	0,49	0,65	0,23	1,42
Kidney	7	1,33	7	0,49	0,59	0,23	1,28
Stomach	7	1,33	7	0,49	0,32	0,13	0,80
Skin other	6	1,14	6	0,42	0,56	0,20	1,25
Other specified	6	1,14	6	0,42	0,50	0,18	1,15
Myeloma	5	0,95	5	0,35	0,61	0,19	1,41
Naso-Oropharynx	5	0,95	5	0,35	0,51	0,16	1,21
Penis	5	0,95	5	0,35	0,31	0,10	0,83
Bone	4	0,76	4	0,28	0,29	0,07	0,83
Eye	4	0,76	4	0,28	0,28	0,07	0,83
Tongue	3	0,57	3	0,21	0,36	0,07	1,02
Connective tissue	3	0,57	3	0,21	0,36	0,06	1,04
Ill defined	3	0,57	3	0,21	0,26	0,04	0,83
Mesothelioma	2	0,38	2	0,14	0,30	0,03	0,99
Salivary gland	2	0,38	2	0,14	0,16	0,02	0,66
Brain, CNS	2	0,38	2	0,14	0,14	0,01	0,61
Endocrine	2	0,38	2	0,14	0,12	0,01	0,58
Melanoma	2	0,38	2	0,14	0,12	0,01	0,58
Haematology other	1	0,19	1	0,07	0,07	0,00	0,51
Small intestine	1	0,19	1	0,07	0,06	0,00	0,50
Lip	1	0,19	1	0,07	0,04	0,00	0,46
Testis	1	0,19	1	0,07	0,04	0,00	0,46

Coloured Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	8	36,36	8	19,41	30,58	11,78	63,48
BCC	4	18,18	4	9,71	21,25	3,09	61,24
Pancreas	1	4,55	1	2,43	4,71	0,12	25,05
Larynx	1	4,55	1	2,43	4,71	0,12	25,05
Bladder	1	4,55	1	2,43	3,90	0,10	22,86
Brain, CNS	1	4,55	1	2,43	2,81	0,07	20,20
Tongue	1	4,55	1	2,43	2,63	0,07	19,78
Colorectal	1	4,55	1	2,43	2,63	0,07	19,78
Kidney	1	4,55	1	2,43	1,92	0,05	18,38
Non-Hodgkin lymphoma	1	4,55	1	2,43	1,84	0,05	18,24
Connective tissue	1	4,55	1	2,43	1,84	0,05	18,24
Stomach	1	4,55	1	2,43	1,22	0,03	17,27

White Males: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
BCC	308	32,77	308	133,79	72,84	64,60	82,06
Prostate	195	20,74	195	84,71	42,98	36,95	50,00
SCC of skin	106	11,28	106	46,05	23,28	18,89	28,68
Colorectal	51	5,43	51	22,15	12,31	8,94	16,80
Bladder	50	5,32	50	21,72	11,15	8,17	15,19
Primary site unknown	40	4,26	39	16,94	8,81	6,16	12,55
Melanoma	32	3,40	32	13,90	8,81	5,83	12,99
Lung	23	2,45	23	9,99	5,50	3,35	8,83
Testis	9	0,96	9	3,91	3,53	1,55	6,95
Oesophagus	12	1,28	12	5,21	3,10	1,56	5,90
Non-Hodgkin lymphoma	11	1,17	11	4,78	3,00	1,39	5,94
Pancreas	11	1,17	11	4,78	2,29	1,11	4,71
Brain, CNS	8	0,85	8	3,48	2,05	0,86	4,56
Kidney	8	0,85	8	3,48	2,03	0,84	4,53
Other specified	7	0,74	7	3,04	1,87	0,72	4,37
Liver & Bile duct	8	0,85	8	3,48	1,85	0,77	4,24
Larynx	7	0,74	7	3,04	1,73	0,67	4,12
Tongue	6	0,64	6	2,61	1,69	0,52	4,31
Stomach	6	0,64	6	2,61	1,32	0,46	3,53
Myeloma	6	0,64	6	2,61	1,30	0,46	3,48
Kaposi Sarcoma	4	0,43	4	1,74	1,20	0,31	3,56
Skin other	6	0,64	6	2,61	1,10	0,40	3,14
Naso-Oropharynx	3	0,32	3	1,30	0,82	0,16	2,95
Connective tissue	3	0,32	3	1,30	0,79	0,16	2,91
Anus	3	0,32	3	1,30	0,74	0,12	2,89
Endocrine	3	0,32	3	1,30	0,73	0,14	2,79
Eye	3	0,32	3	1,30	0,66	0,12	2,68
Thyroid	2	0,21	2	0,87	0,63	0,08	2,76
Ill defined	2	0,21	2	0,87	0,50	0,05	2,53
Penis	2	0,21	2	0,87	0,42	0,05	2,36
Lip	1	0,11	1	0,43	0,30	0,01	2,28
Mesothelioma	1	0,11	1	0,43	0,18	0,00	2,04
Breast	1	0,11	1	0,43	0,18	0,00	2,04
Leukaemia	1	0,11	1	0,43	0,18	0,00	2,04
Gum	1	0,11	1	0,43	0,18	0,00	2,04

Age-Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x

Site	All ages	Unknown Ages	ALL FEMALES																			
			05-09	10-14	14-Oct	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	1622	0	2,79	1,56	3,53	7,05	10,49	12,78	45,76	64,26	90,69	137,86	201,26	210,96	331,19	283,92	379,21	422,47	567,70	636,65	12	
All sites	1374	0	2,79	1,56	3,53	7,93	11,80	15,00	47,66	67,64	102,11	152,15	209,09	249,05	378,22	352,75	533,04	648,79	1021,86	996,50	10	
Cervix	406	0	0,00	0,00	0,00	0,00	0,66	2,78	12,08	31,57	44,34	63,89	62,62	68,85	89,95	36,57	17,89	45,26	75,69	110,72	47	C53
Breast	331	0	0,00	0,00	0,88	1,76	0,66	1,11	11,44	11,84	18,81	31,94	57,02	57,13	79,73	92,49	100,17	75,44	132,46	83,04	44	C50
BCC	187	0	0,00	0,00	0,00	0,88	0,66	2,22	1,91	1,69	9,41	10,09	6,71	29,30	42,93	53,77	107,32	181,06	264,93	249,12	75	C44
Primary site unknown	114	0	0,70	0,78	0,00	0,88	1,31	1,11	3,18	2,25	4,03	5,04	19,01	7,32	44,98	36,57	32,20	75,44	37,85	110,72	126	C80
Colorectal	59	0	0,00	0,00	0,00	0,00	0,00	0,56	2,54	3,95	0,67	4,20	5,59	7,32	8,18	25,81	42,93	7,54	37,85	0,00	197	C18
Uterus	58	0	0,00	0,00	0,00	0,00	0,00	0,56	1,27	1,13	0,00	4,20	8,95	10,25	26,58	8,60	28,62	45,26	18,92	27,68	222	C54
SCC of skin	55	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,69	2,02	3,36	1,12	5,86	4,09	12,91	42,93	45,26	189,23	110,72	271	C44
Ovary	37	0	0,00	0,00	0,00	0,00	0,66	0,56	3,18	1,13	2,02	2,52	8,95	7,32	6,13	0,00	14,31	15,09	0,00	0,00	428	C56
Melanoma	34	0	0,70	0,00	0,00	0,00	0,00	0,00	0,64	1,13	0,00	2,52	3,35	11,72	6,13	10,75	14,31	7,54	37,85	27,68	391	C43
Lung	29	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,84	0,00	4,39	10,22	4,30	35,77	30,18	18,92	55,36	356	C34
Other specified	28	0	0,00	0,00	0,00	0,00	0,00	1,11	1,91	1,13	2,02	3,36	2,24	2,93	4,09	6,45	7,15	0,00	18,92	55,36	618	C63
Non-Hodgkin lymphoma	27	0	0,00	0,78	0,00	1,76	1,31	0,56	0,64	1,69	1,34	1,68	2,24	2,93	2,04	6,45	7,15	7,54	18,92	27,68	655	C84
Oesophagus	21	0	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,00	0,84	3,35	2,93	10,22	4,30	3,58	15,09	75,69	0,00	774	C15
Vulva	19	0	0,00	0,00	0,00	0,00	0,00	0,00	1,27	2,25	2,02	0,00	2,24	7,32	2,04	2,15	0,00	7,54	0,00	0,00	1037	C51
Bladder	19	0	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,56	0,67	0,84	2,24	0,00	10,22	4,30	14,31	0,00	0,00	55,36	593	C67
Liver & Bile duct	17	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,34	0,84	4,47	1,46	6,13	2,15	0,00	15,09	37,85	27,68	1221	C22
Pancreas	16	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,34	0,00	1,12	1,46	4,09	6,45	10,73	30,18	0,00	0,00	794	C25
Thyroid	16	0	0,00	0,00	0,00	0,00	1,31	0,56	0,64	1,13	0,67	2,52	0,00	1,46	2,04	4,30	0,00	7,54	0,00	27,68	1368	C73
Stomach	15	0	0,00	0,00	0,00	0,00	0,00	1,27	0,00	0,67	0,84	1,12	0,00	4,09	10,75	3,58	7,54	18,92	0,00	897	C16	
Kaposi Sarcoma	14	0	0,00	0,00	0,00	0,00	0,66	0,56	1,91	1,13	0,67	1,68	1,12	2,93	0,00	0,00	0,00	0,00	0,00	27,68	1877	C46
Myeloma	14	0	0,00	0,00	0,00	0,00	0,00	0,56	0,64	0,00	1,34	1,68	3,35	0,00	2,04	2,15	7,15	7,54	0,00	0,00	1058	C90
Hodgkin lymphoma	11	0	0,00	0,00	0,88	0,88	0,66	1,11	0,00	0,00	2,02	0,84	0,00	0,00	2,04	0,00	3,58	0,00	0,00	0,00	1666	C81
Anus	9	0	0,00	0,00	0,00	0,00	0,00	0,00	1,27	0,56	0,00	0,00	1,12	0,00	0,00	2,15	10,73	0,00	18,92	0,00	1264	C21
Brain, CNS	9	0	0,00	0,00	0,88	0,00	0,00	0,56	0,00	0,00	1,34	0,84	2,24	0,00	0,00	4,30	0,00	0,00	0,00	0,00	1969	C71

Leukaemia	8	0	0,70	0,00	0,88	0,88	0,66	0,00	0,00	0,00	0,00	0,00	1,12	0,00	0,00	2,15	3,58	0,00	18,92	0,00	2007	C92
Vagina	7	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,02	0,00	2,24	0,00	0,00	2,15	3,58	0,00	0,00	0,00	2003	C52	
Salivary gland	6	0	0,00	0,00	0,00	0,00	0,00	0,00	1,69	0,67	0,84	0,00	1,46	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4292	C07
Naso-Oropharynx	6	0	0,00	0,00	0,00	0,88	0,00	0,00	0,56	0,67	0,84	0,00	1,46	0,00	2,15	0,00	0,00	0,00	0,00	3049	C11	
Skin other	6	0	0,00	0,00	0,00	0,00	0,66	0,00	0,00	0,00	0,84	0,00	2,93	0,00	2,15	3,58	0,00	0,00	0,00	0,00	1969	C44
Eye	6	0	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,84	3,35	0,00	2,04	0,00	0,00	0,00	0,00	0,00	0,00	2946	C69
Kidney	5	0	0,70	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,84	0,00	1,46	0,00	2,15	0,00	7,54	0,00	0,00	3884	C64	
Ill defined	5	0	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,00	1,34	0,00	0,00	0,00	0,00	3,58	7,54	0,00	0,00	3598	C76	
Tongue	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,84	0,00	0,00	4,09	0,00	3,58	0,00	0,00	0,00	2351	C02	
Mouth	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,84	0,00	1,46	2,04	0,00	0,00	0,00	0,00	0,00	4082	C06	
Small intestine	4	0	0,00	0,00	0,00	0,00	0,66	0,00	0,00	0,00	1,68	0,00	1,46	0,00	0,00	0,00	0,00	0,00	0,00	5264	C17	
Mesothelioma	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	0,00	2,15	7,15	0,00	0,00	0,00	1859	C45	
Bone	3	0	0,00	0,00	0,00	0,00	1,31	0,56	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10696	C41	
Connective tissue	3	0	0,00	0,00	0,00	0,00	0,66	0,00	0,00	0,00	0,00	0,00	1,46	0,00	0,00	7,54	0,00	0,00	0,00	9434	C49	
Larynx	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,15	3,58	0,00	0,00	0,00	3491	C32	
Endocrine	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,24	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8929	C74	
Placenta	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	0,00	0,00	0,00	0,00	0,00	0,00	13699	C58	
Haematology other	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	0,00	0,00	0,00	0,00	0,00	0,00	13699	C96	

Site	ASIAN FEMALES																					
	All ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICR74	ICD10
All sites but C44	12	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32,90	0,00	49,71	67,17	70,25	305,30	207,10	121,77	894,43	0,00	0,00	24	
All sites	12	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32,90	0,00	49,71	67,17	70,25	305,30	207,10	121,77	894,43	0,00	0,00	24	
Breast	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	70,25	101,77	207,10	0,00	0,00	0,00	0,00	53	C50
Uterus	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	49,71	0,00	0,00	101,77	0,00	0,00	447,21	0,00	0,00	133	C54
Primary site unknown	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	101,77	0,00	121,77	0,00	0,00	0,00	90	C80
Cervix	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32,90	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	608	C53
III defined	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	447,21	0,00	0,00		C76
Myeloma	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	67,17	0,00	0,00	0,00	0,00	0,00	0,00	0,00	298	C90

BLACK FEMALES																						
Site	All ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	892	0	2,38	1,84	2,03	6,16	10,93	15,98	51,84	76,71	110,18	151,73	217,88	187,78	309,62	245,07	156,89	221,25	212,63	124,75	13	
All sites but C44	876	0	2,38	1,84	2,03	6,16	10,15	14,59	51,84	72,79	109,18	149,15	217,88	181,52	309,62	237,29	156,89	221,25	212,63	124,75	14	
Cervix	361	0	0,00	0,00	0,00	0,00	0,78	2,78	13,99	38,35	62,10	87,44	84,82	83,46	111,57	62,24	16,81	65,07	47,25	93,57	36	C53
Breast	183	0	0,00	0,00	0,00	1,03	0,78	1,39	13,16	12,52	24,04	27,00	53,22	37,56	66,94	73,91	22,41	39,04	47,25	0,00	60	C50
Primary site unknown	59	0	0,00	0,92	0,00	1,03	1,56	0,69	2,47	3,13	4,01	2,57	18,30	6,26	36,26	27,23	22,41	26,03	0,00	31,19	158	C80
Uterus	40	0	0,00	0,00	0,00	0,00	0,00	0,69	1,65	1,57	0,00	5,14	4,99	12,52	25,10	15,56	28,02	52,06	0,00	0,00	210	C54
Colorectal	21	0	0,00	0,00	0,00	0,00	0,00	0,69	2,47	2,35	1,00	3,86	4,99	2,09	8,37	11,67	0,00	0,00	0,00	0,00	534	C18
Ovary	20	0	0,00	0,00	0,00	0,00	0,78	0,69	3,29	0,78	2,00	1,29	6,65	6,26	5,58	0,00	5,60	0,00	0,00	0,00	608	C56
Non-Hodgkin lymphoma	19	0	0,00	0,92	0,00	2,05	0,78	0,69	0,82	2,35	2,00	1,29	3,33	0,00	2,79	3,89	11,21	13,01	0,00	0,00	623	C84
Oesophagus	18	0	0,00	0,00	0,00	0,00	0,00	0,00	0,82	0,00	0,00	1,29	4,99	2,09	13,95	3,89	5,60	13,01	94,50	0,00	613	C15
Vulva	16	0	0,00	0,00	0,00	0,00	0,00	0,00	1,65	3,13	3,00	0,00	3,33	8,35	2,79	0,00	0,00	0,00	0,00	0,00	899	C51
Other specified	15	0	0,00	0,00	0,00	0,00	0,00	1,39	2,47	0,78	1,00	5,14	3,33	2,09	0,00	3,89	0,00	0,00	0,00	0,00	996	C63
Kaposi Sarcoma	13	0	0,00	0,00	0,00	0,00	0,78	0,69	2,47	1,57	1,00	2,57	1,66	4,17	0,00	0,00	0,00	0,00	0,00	0,00	1342	C46
Hodgkin lymphoma	9	0	0,00	0,00	1,02	1,03	0,78	1,39	0,00	0,00	2,00	1,29	0,00	0,00	2,79	0,00	0,00	0,00	0,00	0,00	1942	C81
Liver & Bile duct	8	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	0,00	4,99	0,00	5,58	3,89	0,00	0,00	23,63	0,00	1294	C22
Myeloma	8	0	0,00	0,00	0,00	0,00	0,00	0,69	0,82	0,00	1,00	2,57	3,33	0,00	0,00	0,00	5,60	0,00	0,00	0,00	1428	C90
Stomach	7	0	0,00	0,00	0,00	0,00	0,00	0,00	1,65	0,00	0,00	1,29	1,66	0,00	2,79	7,78	0,00	0,00	0,00	0,00	1319	C16
Pancreas	7	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	0,00	1,66	2,09	5,58	3,89	5,60	0,00	0,00	0,00	1010	C25
Melanoma	7	0	0,79	0,00	0,00	0,00	0,00	0,00	0,00	0,78	0,00	0,00	1,66	2,09	2,79	3,89	5,60	0,00	0,00	0,00	1137	C43
SCC of skin	7	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,35	1,00	1,29	0,00	2,09	0,00	3,89	0,00	0,00	0,00	0,00	1884	C44
BCC	7	0	0,00	0,00	0,00	0,00	0,00	1,39	0,00	1,57	0,00	1,29	0,00	2,09	0,00	3,89	0,00	0,00	0,00	0,00	1956	C44
Lung	6	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	0,00	0,00	2,09	2,79	3,89	5,60	13,01	0,00	0,00	1302	C34
Anus	5	0	0,00	0,00	0,00	0,00	0,00	0,00	1,65	0,78	0,00	0,00	0,00	0,00	0,00	0,00	11,21	0,00	0,00	0,00	1467	C21
Vagina	5	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,00	0,00	3,33	0,00	0,00	0,00	5,60	0,00	0,00	0,00	1830	C52
Bladder	5	0	0,00	0,00	0,00	0,00	0,00	0,00	0,82	0,78	0,00	0,00	1,66	0,00	5,58	0,00	0,00	0,00	0,00	0,00	2263	C67
Eye	5	0	0,00	0,00	0,00	0,00	0,00	0,69	0,00	0,00	0,00	1,29	4,99	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2870	C69
Thyroid	5	0	0,00	0,00	0,00	0,00	0,00	0,69	0,82	0,78	0,00	0,00	0,00	0,00	2,79	3,89	0,00	0,00	0,00	0,00	2230	C73

Leukaemia	5	0	0,79	0,00	1,02	1,03	0,78	0,00	0,00	0,00	0,00	1,66	0,00	0,00	0,00	0,00	0,00	0,00	3788	C92
Salivary gland	4	0	0,00	0,00	0,00	0,00	0,00	0,00	1,57	0,00	1,29	0,00	2,09	0,00	0,00	0,00	0,00	0,00	4041	C07
Small intestine	4	0	0,00	0,00	0,00	0,00	0,78	0,00	0,00	0,00	2,57	0,00	2,09	0,00	0,00	0,00	0,00	0,00	3677	C17
Brain, CNS	4	0	0,00	0,00	0,00	0,00	0,69	0,00	0,00	1,00	1,29	1,66	0,00	0,00	0,00	0,00	0,00	0,00	4311	C71
Naso-Oropharynx	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,78	0,00	0,00	0,00	2,09	0,00	3,89	0,00	0,00	0,00	2959	C11
Bone	3	0	0,00	0,00	0,00	0,00	1,56	0,69	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8889	C41
Tongue	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,58	0,00	0,00	0,00	0,00	3585	C02
Mouth	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,78	0,00	0,00	0,00	2,09	0,00	0,00	0,00	0,00	6969	C06
Skin other	2	0	0,00	0,00	0,00	0,00	0,78	0,00	0,00	0,00	0,00	0,00	2,09	0,00	0,00	0,00	0,00	0,00	6969	C44
Connective tissue	2	0	0,00	0,00	0,00	0,00	0,78	0,00	0,00	0,00	0,00	0,00	2,09	0,00	0,00	0,00	0,00	0,00	6969	C49
Kidney	2	0	0,79	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,89	0,00	0,00	0,00	4274	C64
III defined	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,82	0,00	0,00	0,00	0,00	0,00	0,00	5,60	0,00	0,00	3116	C76
Endocrine	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,66	0,00	0,00	0,00	0,00	0,00	12049	C74

Site	COLOURED FEMALES																					
	All ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	21	0	0,00	0,00	0,00	32,76	0,00	0,00	61,22	18,98	44,32	126,98	74,45	102,21	132,95	166,90	172,36	0,00	0,00	0,00	22	
All sites	20	0	0,00	0,00	0,00	32,76	0,00	0,00	61,22	18,98	44,32	126,98	74,45	102,21	132,95	166,90	172,36	0,00	517,89	0,00	22	
Breast	9	0	0,00	0,00	0,00	32,76	0,00	0,00	30,61	18,98	22,16	63,49	0,00	51,11	66,48	55,63	0,00	0,00	0,00	0,00	59	C50
Cervix	4	0	0,00	0,00	0,00	0,00	0,00	0,00	30,61	0,00	0,00	31,75	0,00	51,11	0,00	0,00	172,36	0,00	0,00	0,00	70	C53
Liver & Bile duct	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,22	0,00	66,48	0,00	0,00	0,00	0,00	0,00	0,00	193	C22
Tongue	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	31,75	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	630	C02
Salivary gland	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,16	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	903	C07
BCC	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	517,89	0,00	0	C44
Vulva	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,63	0,00	0,00	0,00	0,00	360	C51
Uterus	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,22	0,00	0,00	0,00	0,00	0,00	0,00	0,00	538	C54
Brain, CNS	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,63	0,00	0,00	0,00	0,00	360	C71

WHITE FEMALES																						
Site	All ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	697	0	8,97	0,00	18,88	8,33	21,68	13,08	50,01	99,98	156,48	232,52	285,81	319,95	316,00	382,01	648,17	405,15	482,36	569,78	8	
All sites	466	0	8,97	0,00	18,88	16,66	28,91	26,16	71,45	105,24	260,80	313,63	329,30	456,23	477,51	555,65	1014,90	733,65	1010,66	959,63	6	
BCC	179	0	0,00	0,00	0,00	8,33	7,23	13,08	21,43	5,26	91,28	59,48	37,28	112,58	147,47	138,91	255,86	262,80	298,60	269,90	23	C44
Breast	135	0	0,00	0,00	9,44	0,00	0,00	0,00	7,14	21,05	19,56	81,11	118,05	112,58	91,29	121,55	204,69	76,65	114,85	89,97	26	C50
Primary site unknown	53	0	8,97	0,00	0,00	0,00	0,00	6,54	14,29	0,00	13,04	21,63	37,28	11,85	56,18	57,88	34,11	87,60	45,94	89,97	77	C80
SCC of skin	48	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,04	16,22	6,21	17,78	14,04	28,94	102,34	65,70	229,70	119,95	101	C44
Cervix	40	0	0,00	0,00	0,00	0,00	0,00	6,54	7,14	31,57	26,08	37,85	31,07	35,55	28,09	5,79	8,53	10,95	45,94	29,99	92	C53
Colorectal	38	0	0,00	0,00	0,00	0,00	0,00	0,00	7,14	21,05	0,00	10,81	12,43	23,70	7,02	52,09	102,34	10,95	45,94	0,00	85	C18
Melanoma	27	0	0,00	0,00	0,00	0,00	0,00	0,00	7,14	5,26	0,00	16,22	12,43	41,48	14,04	23,15	25,59	10,95	45,94	29,99	138	C43
Lung	23	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,41	0,00	11,85	28,09	5,79	76,76	32,85	22,97	59,98	157	C34
Ovary	17	0	0,00	0,00	0,00	0,00	0,00	0,00	7,14	5,26	6,52	10,81	24,85	11,85	7,02	0,00	25,59	21,90	0,00	0,00	202	C56
Uterus	14	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	24,85	5,93	21,07	0,00	25,59	10,95	22,97	29,99	259	C54
Bladder	14	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	5,41	6,21	0,00	21,07	11,58	34,11	0,00	0,00	59,98	236	C67
Other specified	13	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,26	13,04	0,00	0,00	5,93	14,04	11,58	17,06	0,00	22,97	59,98	299	C63
Thyroid	11	0	0,00	0,00	0,00	0,00	14,46	0,00	0,00	5,26	6,52	16,22	0,00	5,93	0,00	5,79	0,00	10,95	0,00	29,99	370	C73
Pancreas	9	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	0,00	0,00	0,00	11,58	17,06	43,80	0,00	0,00	569	C25
Stomach	8	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	0,00	0,00	7,02	17,36	8,53	10,95	22,97	0,00	508	C16
Non-Hodgkin lymphoma	8	0	0,00	0,00	0,00	0,00	7,23	0,00	0,00	0,00	0,00	5,41	0,00	11,85	0,00	11,58	0,00	0,00	22,97	29,99	555	C84
Liver & Bile duct	7	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	5,41	0,00	5,93	0,00	0,00	0,00	21,90	22,97	29,99	1120	C22
Myeloma	5	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	0,00	0,00	7,02	5,79	8,53	10,95	0,00	0,00	718	C90
Anus	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,21	0,00	0,00	5,79	8,53	0,00	22,97	0,00	975	C21
Skin other	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,41	0,00	5,93	0,00	5,79	8,53	0,00	0,00	0,00	780	C44
Mesothelioma	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,93	0,00	5,79	17,06	0,00	0,00	0,00	695	C45

Brain, CNS	4	0	0,00	0,00	9,44	0,00	0,00	0,00	0,00	6,52	0,00	6,21	0,00	0,00	5,79	0,00	0,00	0,00	0,00	716	C71	
Naso-Oropharynx	3	0	0,00	0,00	0,00	8,33	0,00	0,00	0,00	6,52	5,41	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	988	C11	
Oesophagus	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,93	0,00	5,79	0,00	10,95	0,00	0,00	1707	C15	
Kidney	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,41	0,00	5,93	0,00	0,00	0,00	0,00	10,95	0,00	0,00	1764	C64	
Leukaemia	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,79	8,53	0,00	22,97	0,00	1397	C92	
Mouth	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,41	0,00	0,00	7,02	0,00	0,00	0,00	0,00	0,00	0,00	1610	C06	
Larynx	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,79	8,53	0,00	0,00	0,00	1397	C32	
Vulva	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,93	0,00	0,00	0,00	10,95	0,00	0,00	3373	C51	
Vagina	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	0,00	0,00	0,00	5,79	0,00	0,00	0,00	0,00	1625	C52	
III defined	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,04	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1534	C76	
Hodgkin lymphoma	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	0,00	0,00	0,00	0,00	8,53	0,00	0,00	0,00	1329	C81	
Tongue	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,53	0,00	0,00	0,00	2345	C02	
Salivary gland	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,26	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3803	C07	
Kaposi Sarcoma	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29,99	0	C46
Connective tissue	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,95	0,00	0,00	0	C49	
Placenta	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,93	0,00	0,00	0,00	0,00	0,00	0,00	3373	C58	
Eye	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,02	0,00	0,00	0,00	0,00	0,00	2850	C69	
Endocrine	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,21	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3221	C74	
Haematology other	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,93	0,00	0,00	0,00	0,00	0,00	0,00	3373	C96	

Site	ALL MALES																					
	All ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	1509	1	0,7	4,0	2,6	5,2	3,4	14,4	20,4	23,9	31,1	65,1	109,5	184,8	327,1	406,6	452,0	511,0	367,0	220,4	13	
All sites	1063	0	1,4	4,0	2,6	5,2	4,1	14,4	25,3	27,7	43,3	85,8	153,0	261,0	437,5	553,0	665,1	861,3	834,1	426,1	9	
Prostate	406	1	0,0	0,0	0,0	0,0	0,0	0,0	0,7	1,3	4,1	5,9	29,9	71,9	154,1	216,4	245,4	229,7	166,8	117,6	28	C61
BCC	320	0	0,0	0,0	0,0	0,0	0,7	0,0	2,8	2,6	9,8	14,8	37,3	57,2	79,9	102,7	151,7	218,2	300,3	205,7	44	C44
SCC of skin	114	0	0,0	0,0	0,0	0,0	0,0	0,0	2,1	1,3	2,5	5,9	6,2	14,7	30,4	35,0	58,1	126,3	144,6	0,0	129	C44
Primary site unknown	85	0	0,0	0,8	0,9	0,9	0,0	0,0	0,7	1,9	5,7	7,9	9,9	19,1	19,0	24,0	32,3	51,7	0,0	14,7	163	C80
Colorectal	78	0	0,0	0,0	0,0	0,9	0,0	0,6	0,0	2,6	0,8	7,9	11,2	13,2	15,2	32,8	32,3	34,5	66,7	0,0	171	C18
Bladder	61	0	0,0	0,0	0,9	0,0	0,0	0,0	0,0	0,6	0,8	3,9	3,7	10,3	20,9	17,5	35,5	51,7	55,6	0,0	213	C67
Lung	43	0	0,0	0,0	0,0	0,9	0,7	0,0	0,7	0,6	0,8	3,0	2,5	7,3	13,3	19,7	12,9	28,7	11,1	29,4	321	C34
Oesophagus	39	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,6	1,6	3,9	0,0	8,8	20,9	15,3	12,9	17,2	0,0	14,7	312	C15
Melanoma	34	0	0,0	0,0	0,0	0,0	0,0	1,2	1,4	1,3	0,8	1,0	7,5	2,9	3,8	15,3	9,7	11,5	22,2	29,4	446	C43
Non-Hodgkin lymphoma	34	0	0,0	0,8	0,0	0,0	0,0	1,8	0,7	3,2	0,8	6,9	6,2	0,0	3,8	6,6	12,9	5,7	0,0	14,7	458	C84
Kaposi Sarcoma	30	0	0,0	0,0	0,0	0,0	0,7	1,2	5,6	1,3	4,9	3,9	5,0	2,9	0,0	2,2	0,0	0,0	0,0	0,0	722	C46
Pancreas	21	0	0,0	0,0	0,0	0,0	0,0	0,0	0,7	0,0	1,6	1,0	2,5	1,5	5,7	10,9	12,9	5,7	11,1	0,0	543	C25
Larynx	21	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	3,0	3,7	4,4	15,2	4,4	6,5	0,0	0,0	0,0	539	C32
Liver & Bile duct	18	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	2,6	0,8	2,0	2,5	1,5	5,7	8,7	0,0	5,7	0,0	0,0	842	C22
Kidney	16	0	0,0	0,8	0,0	0,0	0,0	0,6	0,0	0,0	0,8	0,0	3,7	4,4	3,8	6,6	3,2	5,7	0,0	0,0	836	C64
Stomach	14	0	0,0	0,0	0,0	0,0	0,0	1,2	2,1	1,3	0,8	0,0	1,2	1,5	1,9	0,0	3,2	11,5	0,0	0,0	1509	C16
Other specified	14	0	0,0	0,0	0,0	0,0	0,0	0,6	0,7	0,0	0,0	2,0	3,7	5,9	0,0	0,0	9,7	0,0	0,0	0,0	887	C63
Skin other	12	0	0,7	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	4,4	0,0	8,7	3,2	5,7	22,2	0,0	1172	C44
Testis	12	0	0,0	0,0	0,0	0,0	0,7	1,2	2,8	0,0	2,5	1,0	0,0	1,5	0,0	0,0	0,0	0,0	0,0	0,0	2084	C62
Tongue	11	0	0,0	0,0	0,0	0,0	0,0	0,6	0,0	0,0	0,0	1,0	0,0	0,0	9,5	6,6	0,0	5,7	0,0	0,0	1133	C02
Anus	11	0	0,0	0,0	0,0	0,0	0,0	0,0	2,1	0,6	0,0	0,0	2,5	1,5	3,8	0,0	3,2	5,7	0,0	0,0	1456	C21
Brain, CNS	11	0	0,7	0,0	0,9	0,0	0,0	0,0	0,0	0,6	0,0	2,0	2,5	1,5	1,9	0,0	0,0	11,5	0,0	0,0	1991	C71
Myeloma	11	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	1,0	0,0	4,4	5,7	4,4	0,0	11,5	0,0	0,0	1293	C90
Leukaemia	11	0	0,0	0,0	0,0	0,9	0,7	1,2	0,0	1,3	0,8	0,0	1,2	1,5	0,0	4,4	0,0	0,0	0,0	0,0	1676	C92
Hodgkin lymphoma	10	0	0,0	0,8	0,0	0,0	0,0	1,8	1,4	0,0	0,8	1,0	1,2	1,5	0,0	0,0	0,0	0,0	0,0	0,0	2345	C81

Mouth	9	0	0,0	0,0	0,0	0,0	0,0	0,0	0,6	0,8	1,0	1,2	2,9	3,8	2,2	0,0	0,0	0,0	0,0	1587	C06	
Naso-Oropharynx	8	0	0,0	0,0	0,0	0,0	0,6	0,0	0,0	0,0	0,0	0,0	0,0	7,6	4,4	0,0	0,0	11,1	0,0	1590	C11	
Breast	8	0	0,0	0,0	0,0	0,0	0,6	0,0	0,6	0,0	0,0	1,2	1,5	3,8	0,0	3,2	5,7	0,0	0,0	1822	C50	
Connective tissue	7	0	0,0	0,0	0,0	0,9	0,0	0,0	0,0	0,0	1,0	0,0	4,4	1,9	0,0	0,0	0,0	11,1	0,0	2451	C49	
Penis	7	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,8	3,0	1,2	1,5	0,0	0,0	3,2	0,0	0,0	0,0	2058	C60	
Eye	7	0	0,0	0,0	0,0	0,0	0,0	0,6	0,0	0,6	0,0	0,0	1,2	0,0	3,8	0,0	0,0	5,7	11,1	0,0	3185	C69
Endocrine	5	0	0,0	0,0	0,0	0,0	0,0	0,0	0,6	0,0	0,0	1,2	2,9	0,0	2,2	0,0	0,0	0,0	0,0	2858	C74	
Ill defined	5	0	0,0	0,8	0,0	0,0	0,0	0,0	0,6	0,8	0,0	0,0	0,0	0,0	0,0	6,5	0,0	0,0	0,0	2294	C76	
Bone	4	0	0,0	0,0	0,0	0,9	0,7	0,6	0,0	0,0	0,0	0,0	0,0	1,5	0,0	0,0	0,0	0,0	0,0	5525	C41	
Mesothelioma	3	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	6,5	5,7	0,0	0,0	3096	C45	
Lip	2	0	0,0	0,0	0,0	0,0	0,0	0,0	0,7	0,0	0,0	0,0	0,0	0,0	1,9	0,0	0,0	0,0	0,0	7693	C00	
Salivary gland	2	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	2,9	0,0	0,0	0,0	0,0	0,0	6826	C07	
Thyroid	2	0	0,0	0,0	0,0	0,0	0,0	0,0	0,6	0,0	1,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	12270	C73	
Gum	1	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	2,2	0,0	0,0	0,0	0,0	9133	C03	
Small intestine	1	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	1,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	20203	C17	
Haematology other	1	0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	1,2	0,0	0,0	0,0	0,0	0,0	0,0	0,0	16130	C96	

Site	All ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	19	0	0,00	0,00	0,00	0,00	0,00	71,66	26,66	0,00	32,40	75,81	55,25	0,00	176,31	371,90	796,47	329,24	0,00	1425,27	13	
All sites	18	0	0,00	0,00	0,00	0,00	0,00	71,66	26,66	0,00	32,40	75,81	110,51	0,00	176,31	371,90	796,47	329,24	0,00	1425,27	13	
Lung	5	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	88,15	123,97	199,12	329,24	0,00	1425,27	49	C34
Primary site unknown	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32,40	37,91	0,00	0,00	0,00	0,00	199,12	0,00	0,00	0,00	75	C80
Colorectal	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	398,23	0,00	0,00	0,00	51	C18
Prostate	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,25	0,00	0,00	123,97	0,00	0,00	0,00	0,00	112	C61
Testis	2	0	0,00	0,00	0,00	0,00	0,00	35,83	26,66	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	321	C62
Tongue	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,91	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	528	C02
Larynx	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	88,15	0,00	0,00	0,00	0,00	0,00	227	C32
BCC	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,25	0,00	0,00	0,00	0,00	0,00	0,00	0,00	362	C44
Other specified	1	0	0,00	0,00	0,00	0,00	0,00	35,83	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	559	C63
Bladder	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	123,97	0,00	0,00	0,00	0,00	162	C67

Site	BLACK MALES																					
	All ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	528	1	0,79	4,46	2,07	5,30	2,25	10,00	15,45	17,36	21,83	35,33	65,32	146,41	261,64	304,62	306,31	321,98	318,91	194,72	17	
All sites	507	0	1,59	4,46	2,07	5,30	2,25	10,00	16,92	17,36	24,26	35,33	65,32	154,65	267,59	315,50	319,07	355,87	389,77	194,72	17	
Prostate	201	1	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,67	2,43	3,21	13,06	51,55	133,79	203,08	223,35	203,36	248,04	194,72	32	C61
Primary site unknown	42	0	0,00	0,89	1,03	1,06	0,00	0,00	0,74	0,67	4,85	4,28	5,81	18,56	17,84	10,88	19,14	33,89	0,00	0,00	234	C80
Oesophagus	27	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,81	3,21	0,00	10,31	20,81	21,76	12,76	33,89	0,00	0,00	285	C15
Kaposi Sarcoma	26	0	0,00	0,00	0,00	0,00	0,75	1,25	5,15	1,34	4,85	2,14	5,81	4,12	0,00	0,00	0,00	0,00	0,00	0,00	788	C46
Colorectal	24	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,81	4,28	4,35	10,31	14,87	18,13	0,00	0,00	0,00	0,00	375	C18
Non-Hodgkin lymphoma	22	0	0,00	0,89	0,00	0,00	0,00	1,25	0,74	3,34	0,81	4,28	4,35	0,00	5,95	3,63	12,76	0,00	0,00	0,00	527	C84
Lung	15	0	0,00	0,00	0,00	1,06	0,00	0,00	0,74	0,67	0,81	1,07	2,90	4,12	5,95	7,25	12,76	0,00	0,00	0,00	536	C34
Larynx	12	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,21	4,35	6,19	5,95	0,00	6,38	0,00	0,00	0,00	767	C32
Liver & Bile duct	10	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,00	0,81	2,14	0,00	0,00	8,92	3,63	0,00	0,00	0,00	0,00	1143	C22
Hodgkin lymphoma	10	0	0,00	0,89	0,00	0,00	0,00	1,87	1,47	0,00	0,81	1,07	1,45	2,06	0,00	0,00	0,00	0,00	0,00	0,00	2080	C81
Leukaemia	10	0	0,00	0,00	0,00	1,06	0,75	1,25	0,00	1,34	0,81	0,00	1,45	2,06	0,00	3,63	0,00	0,00	0,00	0,00	1620	C92
Mouth	9	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,81	1,07	1,45	4,12	5,95	3,63	0,00	0,00	0,00	0,00	1130	C06
Pancreas	9	0	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,00	1,62	0,00	2,90	2,06	0,00	7,25	0,00	0,00	35,43	0,00	1373	C25
Bladder	9	0	0,00	0,00	1,03	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4,35	4,12	2,97	7,25	0,00	0,00	0,00	0,00	1015	C67
Anus	8	0	0,00	0,00	0,00	0,00	0,00	0,00	1,47	0,67	0,00	0,00	2,90	2,06	5,95	0,00	0,00	0,00	0,00	0,00	1533	C21
SCC of skin	8	0	0,00	0,00	0,00	0,00	0,00	0,00	1,47	0,00	0,00	0,00	0,00	2,06	5,95	0,00	6,38	16,95	35,43	0,00	1262	C44
Stomach	7	0	0,00	0,00	0,00	0,00	0,00	1,25	2,21	0,67	0,81	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4049	C16
BCC	7	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,43	0,00	0,00	0,00	0,00	3,63	6,38	16,95	35,43	0,00	1608	C44
Breast	7	0	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,67	0,00	0,00	1,45	2,06	5,95	0,00	0,00	16,95	0,00	0,00	1861	C50
Kidney	7	0	0,00	0,89	0,00	0,00	0,00	0,62	0,00	0,00	0,00	0,00	1,45	4,12	0,00	7,25	0,00	0,00	0,00	0,00	1396	C64
Skin other	6	0	0,79	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,19	0,00	7,25	0,00	0,00	0,00	0,00	1406	C44
Other specified	6	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,07	2,90	4,12	0,00	0,00	6,38	0,00	0,00	0,00	1383	C63
Naso-Oropharynx	5	0	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,00	0,00	0,00	0,00	0,00	5,95	7,25	0,00	0,00	0,00	0,00	1448	C11
Penis	5	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,81	3,21	1,45	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3657	C60
Myeloma	5	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,06	8,92	0,00	0,00	16,95	0,00	0,00	1822	C90

Bone	4	0	0,00	0,00	0,00	1,06	0,75	0,62	0,00	0,00	0,00	0,00	0,00	2,06	0,00	0,00	0,00	0,00	0,00	4455	C41	
Eye	4	0	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,67	0,00	0,00	1,45	0,00	2,97	0,00	0,00	0,00	0,00	0,00	3503	C69
Tongue	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,92	0,00	0,00	0,00	0,00	0,00	2243	C02
Connective tissue	3	0	0,00	0,00	0,00	1,06	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,06	0,00	0,00	0,00	0,00	35,43	0,00	6411	C49
III defined	3	0	0,00	0,89	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,00	0,00	0,00	0,00	6,38	0,00	0,00	0,00	2519	C76
Salivary gland	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4,12	0,00	0,00	0,00	0,00	0,00	0,00	4855	C07
Melanoma	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,00	2,06	0,00	0,00	0,00	0,00	0,00	0,00	7327	C43
Mesothelioma	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,38	16,95	0,00	0,00	0,00	3135	C45
Brain, CNS	2	0	0,79	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13699	C71
Endocrine	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,00	2,06	0,00	0,00	0,00	0,00	0,00	0,00	7327	C74
Lip	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27028	C00
Small intestine	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,07	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18692	C17
Testis	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27028	C62
Haematology other	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,45	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13794	C96

Site	COLOURED MALES																					
	All ages	Unknown Ages	0-4	5-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	22	0	0,00	0,00	31,28	0,00	0,00	0,00	0,00	20,36	0,00	61,32	46,67	143,96	353,04	262,71	390,31	1316,57	0,00	0,00	16	
All sites	18	0	0,00	0,00	31,28	0,00	0,00	0,00	0,00	20,36	26,69	91,98	46,67	143,96	470,72	262,71	390,31	1316,57	0,00	2620,91	14	
Prostate	8	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	46,67	95,97	117,68	87,57	195,15	1316,57	0,00	0,00	37	C61
BCC	4	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26,69	30,66	0,00	0,00	0,00	117,68	0,00	0,00	0,00	0,00	2620,91	115	C44
Tongue	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	87,57	0,00	0,00	0,00	0,00	229	C02
Stomach	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,36	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	983	C16
Colorectal	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	87,57	0,00	0,00	0,00	0,00	229	C18
Pancreas	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	117,68	0,00	0,00	0,00	0,00	0,00	170	C25
Larynx	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	117,68	0,00	0,00	0,00	0,00	0,00	170	C32
Connective tissue	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,66	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	653	C49
Kidney	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	47,99	0,00	0,00	0,00	0,00	0,00	0,00	417	C64
Bladder	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	195,15	0,00	0,00	0,00	103	C67
Brain, CNS	1	0	0,00	0,00	31,28	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	640	C71
Non-Hodgkin lymphoma	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,66	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	653	C84

		WHITE MALES																				
Site	All ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites but C44	940	0	0,00	0,00	0,00	7,26	14,27	44,19	48,60	54,82	54,47	147,49	247,18	321,15	594,18	565,78	763,23	971,18	1023,98	689,62	7	
All sites	520	0	0,00	0,00	0,00	7,26	21,41	44,19	83,32	87,71	114,40	249,21	452,15	617,59	1007,86	942,97	1331,22	1826,41	2730,62	1586,12	5	
BCC	308	0	0,00	0,00	0,00	0,00	7,14	0,00	27,77	21,93	43,58	71,20	174,83	240,86	308,37	271,10	408,24	536,33	1109,31	896,51	13	C44
Prostate	195	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,48	10,89	15,26	78,37	135,87	263,25	241,64	354,99	376,88	341,33	275,85	19	C61
SCC of skin	106	0	0,00	0,00	0,00	0,00	0,00	0,00	6,94	10,96	16,34	30,52	30,14	55,58	105,30	94,30	150,87	304,40	511,99	0,00	40	C44
Colorectal	51	0	0,00	0,00	0,00	7,26	0,00	7,36	0,00	16,45	0,00	20,34	36,17	24,70	22,56	53,04	71,00	86,97	256,00	0,00	78	C18
Bladder	50	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,48	5,45	20,34	0,00	30,88	75,21	29,47	88,75	130,46	213,33	0,00	79	C67
Primary site unknown	39	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,96	0,00	15,26	24,11	24,70	30,09	47,15	53,25	101,47	0,00	68,96	98	C80
Melanoma	32	0	0,00	0,00	0,00	0,00	0,00	14,73	13,89	5,48	5,45	5,09	36,17	6,18	15,04	41,25	26,62	28,99	85,33	137,92	118	C43
Lung	23	0	0,00	0,00	0,00	0,00	7,14	0,00	0,00	0,00	0,00	10,17	0,00	18,53	30,09	35,36	8,87	57,98	42,67	68,96	182	C34
Oesophagus	12	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,45	5,09	0,00	6,18	30,09	5,89	17,75	14,50	0,00	68,96	284	C15
Pancreas	11	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,09	0,00	0,00	15,04	17,68	35,50	14,50	0,00	0,00	273	C25
Non-Hodgkin lymphoma	11	0	0,00	0,00	0,00	0,00	0,00	7,36	0,00	0,00	0,00	10,17	12,06	0,00	0,00	11,79	17,75	14,50	0,00	68,96	339	C84
Testis	9	0	0,00	0,00	0,00	0,00	7,14	7,36	13,89	0,00	16,34	5,09	0,00	6,18	0,00	0,00	0,00	0,00	0,00	0,00	358	C62
Liver & Bile duct	8	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,48	0,00	0,00	12,06	6,18	0,00	17,68	0,00	14,50	0,00	0,00	484	C22
Kidney	8	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,45	0,00	12,06	0,00	15,04	5,89	8,87	14,50	0,00	0,00	423	C64
Brain, CNS	8	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,17	12,06	6,18	7,52	0,00	0,00	28,99	0,00	0,00	557	C71
Larynx	7	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,09	11,79	8,87	0,00	0,00	0,00	395	C32
Other specified	7	0	0,00	0,00	0,00	0,00	0,00	0,00	6,94	0,00	0,00	5,09	6,03	12,35	0,00	0,00	17,75	0,00	0,00	0,00	416	C63
Tongue	6	0	0,00	0,00	0,00	0,00	0,00	7,36	0,00	0,00	0,00	0,00	0,00	0,00	15,04	11,79	0,00	14,50	0,00	0,00	585	C02
Stomach	6	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,03	6,18	7,52	0,00	8,87	28,99	0,00	0,00	700	C16
Skin other	6	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,79	8,87	14,50	85,33	0,00	969	C44
Myeloma	6	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,09	0,00	12,35	0,00	11,79	0,00	14,50	0,00	0,00	685	C90
Kaposi Sarcoma	4	0	0,00	0,00	0,00	0,00	0,00	0,00	6,94	0,00	0,00	10,17	0,00	0,00	0,00	5,89	0,00	0,00	0,00	0,00	870	C46
Naso-Oropharynx	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	15,04	0,00	0,00	0,00	42,67	0,00	1330	C11
Anus	3	0	0,00	0,00	0,00	0,00	0,00	0,00	6,94	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,87	14,50	0,00	0,00	1266	C21

Connective tissue	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,35	7,52	0,00	0,00	0,00	0,00	1007	C49		
Eye	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,52	0,00	0,00	14,50	42,67	0,00	2660	C69	
Endocrine	3	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,03	6,18	0,00	5,89	0,00	0,00	0,00	1105	C74	
Penis	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,18	0,00	0,00	8,87	0,00	0,00	0,00	1329	C60	
Thyroid	2	0	0,00	0,00	0,00	0,00	0,00	0,00	5,48	0,00	5,09	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1893	C73	
III defined	2	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,45	0,00	0,00	0,00	0,00	0,00	0,00	8,87	0,00	0,00	0,00	1397	C76
Lip	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,52	0,00	0,00	0,00	0,00	0,00	2660	C00	
Gum	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,89	0,00	0,00	0,00	0,00	3396	C03	
Mesothelioma	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,87	0,00	0,00	0,00	2255	C45	
Breast	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,87	0,00	0,00	0,00	2255	C50
Leukaemia	1	0	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,89	0,00	0,00	0,00	0,00	3396	C92	

Frequency of Cancer by Age Group

Site	All Ages	ALL FEMALES																			
		Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	1622	0	4	2	4	9	18	27	75	120	152	181	187	170	184	164	149	86	54	36	
All sites but C44	1374	0	4	2	4	8	16	23	72	114	135	164	180	144	161	132	106	56	30	23	
Cervix	406	0	0	0	0	0	1	5	19	56	66	76	56	47	44	17	5	6	4	4	C53
Breast	331	0	0	0	1	2	1	2	18	21	28	38	51	39	39	43	28	10	7	3	C50
BCC	187	0	0	0	0	1	1	4	3	3	14	12	6	20	21	25	30	24	14	9	C44
Primary site unknown	114	0	1	1	0	1	2	2	5	4	6	6	17	5	22	17	9	10	2	4	C80
Colorectal	59	0	0	0	0	0	0	1	4	7	1	5	5	5	4	12	12	1	2	0	C18
Uterus	58	0	0	0	0	0	0	1	2	2	0	5	8	7	13	4	8	6	1	1	C54
SCC of skin	55	0	0	0	0	0	0	0	0	3	3	4	1	4	2	6	12	6	10	4	C44
Ovary	37	0	0	0	0	0	1	1	5	2	3	3	8	5	3	0	4	2	0	0	C56
Melanoma	34	0	1	0	0	0	0	0	1	2	0	3	3	8	3	5	4	1	2	1	C43
Lung	29	0	0	0	0	0	0	0	0	0	1	1	0	3	5	2	10	4	1	2	C34
Other specified	28	0	0	0	0	0	0	2	3	2	3	4	2	2	2	3	2	0	1	2	C63
Non-Hodgkin lymphoma	27	0	0	1	0	2	2	1	1	3	2	2	2	1	3	2	1	1	1	1	C84
Oesophagus	21	0	0	0	0	0	0	0	1	0	0	1	3	2	5	2	1	2	4	0	C15
Vulva	19	0	0	0	0	0	0	0	2	4	3	0	2	5	1	1	0	1	0	0	C51
Bladder	19	0	0	0	0	0	0	0	1	1	1	1	2	0	5	2	4	0	0	2	C67
Liver & Bile duct	17	0	0	0	0	0	0	0	0	0	2	1	4	1	3	1	0	2	2	1	C22
Pancreas	16	0	0	0	0	0	0	0	0	0	0	2	0	1	1	2	3	3	4	0	C25
Thyroid	16	0	0	0	0	0	2	1	1	2	1	3	0	1	1	2	0	1	0	1	C73
Stomach	15	0	0	0	0	0	0	0	2	0	1	1	1	0	2	5	1	1	1	0	C16
Kaposi Sarcoma	14	0	0	0	0	0	1	1	3	2	1	2	1	2	0	0	0	0	0	1	C46
Myeloma	14	0	0	0	0	0	0	1	1	0	2	2	3	0	1	1	2	1	0	0	C90
Hodgkin lymphoma	11	0	0	0	1	1	1	2	0	0	3	1	0	0	1	0	1	0	0	0	C81
Anus	9	0	0	0	0	0	0	0	2	1	0	0	1	0	0	1	3	0	1	0	C21

Brain, CNS	9	0	0	0	1	0	0	1	0	0	2	1	2	0	0	2	0	0	0	0	C71
Leukaemia	8	0	1	0	1	1	1	0	0	0	0	0	1	0	0	1	1	0	1	0	C92
Vagina	7	0	0	0	0	0	0	0	0	0	3	0	2	0	0	1	1	0	0	0	C52
Salivary gland	6	0	0	0	0	0	0	0	0	3	1	1	0	1	0	0	0	0	0	0	C07
Naso-Oropharynx	6	0	0	0	0	1	0	0	0	1	1	1	0	1	0	1	0	0	0	0	C11
Skin other	6	0	0	0	0	0	1	0	0	0	0	1	0	2	0	1	1	0	0	0	C44
Eye	6	0	0	0	0	0	0	1	0	0	0	1	3	0	1	0	0	0	0	0	C69
Kidney	5	0	1	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0	0	C64
Ill defined	5	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	1	1	0	0	C76
Tongue	4	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	1	0	0	0	C02
Mouth	4	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0	0	0	0	C06
Small intestine	4	0	0	0	0	0	1	0	0	0	0	2	0	1	0	0	0	0	0	0	C17
Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2	0	0	0	C45
Bone	3	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	C41
Connective tissue	3	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	C49
Larynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	C32
Endocrine	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	C74
Placenta	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C58
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C96

Site	ASIAN FEMALES																	
	All Ages		Unknown Ages															
	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	12	0	0	0	0	0	0	1	0	1	1	1	3	2	1	2	0	0
All sites but C44	12	0	0	0	0	0	0	1	0	1	1	1	3	2	1	2	0	0
Breast	4	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	C50
Uterus	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	C54
Primary site unknown	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	C80
Cervix	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	C53
Ill defined	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	C76
Myeloma	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C90

Site	BLACK FEMALES																				
	All Ages	Unknown Ages	0-4	5-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	892	0	3	2	2	6	14	23	63	98	110	118	131	90	111	63	28	17	9	4	
All sites but C44	876	0	3	2	2	6	13	21	63	93	109	116	131	87	111	61	28	17	9	4	
Cervix	361	0	0	0	0	0	1	4	17	49	62	68	51	40	40	16	3	5	2	3	C53
Breast	183	0	0	0	0	1	1	2	16	16	24	21	32	18	24	19	4	3	2	0	C50
Primary site unknown	59	0	0	1	0	1	2	1	3	4	4	2	11	3	13	7	4	2	0	1	C80
Uterus	40	0	0	0	0	0	0	1	2	2	0	4	3	6	9	4	5	4	0	0	C54
Colorectal	21	0	0	0	0	0	0	1	3	3	1	3	3	1	3	3	0	0	0	0	C18
Ovary	20	0	0	0	0	0	1	1	4	1	2	1	4	3	2	0	1	0	0	0	C56
Non-Hodgkin lymphoma	19	0	0	1	0	2	1	1	1	3	2	1	2	0	1	1	2	1	0	0	C84
Oesophagus	18	0	0	0	0	0	0	0	1	0	0	1	3	1	5	1	1	1	4	0	C15
Vulva	16	0	0	0	0	0	0	0	2	4	3	0	2	4	1	0	0	0	0	0	C51
Other specified	15	0	0	0	0	0	0	2	3	1	1	4	2	1	0	1	0	0	0	0	C63
Kaposi Sarcoma	13	0	0	0	0	0	1	1	3	2	1	2	1	2	0	0	0	0	0	0	C46
Hodgkin lymphoma	9	0	0	0	1	1	1	2	0	0	2	1	0	0	1	0	0	0	0	0	C81
Liver & Bile duct	8	0	0	0	0	0	0	0	0	0	1	0	3	0	2	1	0	0	1	0	C22
Myeloma	8	0	0	0	0	0	0	1	1	0	1	2	2	0	0	0	1	0	0	0	C90
Stomach	7	0	0	0	0	0	0	0	2	0	0	1	1	0	1	2	0	0	0	0	C16
Pancreas	7	0	0	0	0	0	0	0	0	0	0	1	0	1	1	2	1	1	0	0	C25
Melanoma	7	0	1	0	0	0	0	0	0	1	0	0	1	1	1	1	1	0	0	0	C43
BCC	7	0	0	0	0	0	0	2	0	2	0	1	0	1	0	1	0	0	0	0	C44
SCC of skin	7	0	0	0	0	0	0	0	0	3	1	1	0	1	0	1	0	0	0	0	C44
Lung	6	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	0	0	C34
Anus	5	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	2	0	0	0	C21
Vagina	5	0	0	0	0	0	0	0	0	0	2	0	2	0	0	0	1	0	0	0	C52
Bladder	5	0	0	0	0	0	0	0	1	1	0	0	1	0	2	0	0	0	0	0	C67
Eye	5	0	0	0	0	0	0	1	0	0	0	1	3	0	0	0	0	0	0	0	C69
Thyroid	5	0	0	0	0	0	0	1	1	1	0	0	0	0	1	1	0	0	0	0	C73

Leukaemia	5	0	1	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	C92
Salivary gland	4	0	0	0	0	0	0	0	2	0	1	0	1	0	0	0	0	0	C07
Small intestine	4	0	0	0	0	0	1	0	0	0	2	0	1	0	0	0	0	0	C17
Brain, CNS	4	0	0	0	0	0	0	1	0	0	1	1	1	0	0	0	0	0	C71
Naso-Oropharynx	3	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	0	C11
Bone	3	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	C41
Tongue	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	C02
Mouth	2	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	C06
Skin other	2	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	C44
Connective tissue	2	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	C49
Kidney	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C64
Ill defined	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	C76
Endocrine	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C74

Site	COLOURED FEMALES																				
	All Ages	Unknown Ages	0-4	5-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	21	0	0	0	0	1	0	0	2	1	2	4	2	2	2	3	1	0	1	0	
All sites but C44	20	0	0	0	0	1	0	0	2	1	2	4	2	2	2	3	1	0	0	0	
Breast	9	0	0	0	0	1	0	0	1	1	1	2	0	1	1	1	0	0	0	C50	
Cervix	4	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	1	0	0	C53	
Liver & Bile duct	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	C22	
Tongue	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C02	
Salivary gland	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C07	
BCC	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	C44
Vulva	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C51
Uterus	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C54
Brain, CNS	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C71

WHITE FEMALES

Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10	
All sites	697	0	1	0	2	2	4	4	10	20	40	58	53	77	68	96	119	67	44	32		
All sites but C44	466	0	1	0	2	1	3	2	7	19	24	43	46	54	45	66	76	37	21	19		
BCC	179	0	0	0	0	1	1	2	3	1	14	11	6	19	21	24	30	24	13	9	C44	
Breast	135	0	0	0	1	0	0	0	1	4	3	15	19	19	13	21	24	7	5	3	C50	
Primary site unknown	53	0	1	0	0	0	0	0	1	2	0	2	4	6	2	8	10	4	8	2	3	C80
SCC of skin	48	0	0	0	0	0	0	0	0	0	2	3	1	3	2	5	12	6	10	4	C44	
Cervix	40	0	0	0	0	0	0	1	1	6	4	7	5	6	4	1	1	2	1	C53		
Colorectal	38	0	0	0	0	0	0	0	1	4	0	2	2	4	1	9	12	1	2	0	C18	
Melanoma	27	0	0	0	0	0	0	0	1	1	0	3	2	7	2	4	3	1	2	1	C43	
Lung	23	0	0	0	0	0	0	0	0	0	0	1	0	2	4	1	9	3	1	2	C34	
Ovary	17	0	0	0	0	0	0	0	1	1	1	2	4	2	1	0	3	2	0	0	C56	
Uterus	14	0	0	0	0	0	0	0	0	0	0	0	4	1	3	0	3	1	1	1	C54	
Bladder	14	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2	4	0	0	2	C67	
Other specified	13	0	0	0	0	0	0	0	0	1	2	0	0	1	2	2	2	0	1	2	C63	
Thyroid	11	0	0	0	0	0	2	0	0	1	1	3	0	1	0	1	0	1	0	1	C73	
Pancreas	9	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	2	4	0	0	C25	
Stomach	8	0	0	0	0	0	0	0	0	0	1	0	0	0	1	3	1	1	1	0	C16	
Non-Hodgkin lymphoma	8	0	0	0	0	0	1	0	0	0	0	1	0	2	0	2	0	0	1	1	C84	
Liver & Bile duct	7	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	2	1	1	C22	
Myeloma	5	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	0	0	C90	
Anus	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	0	C21	
Skin other	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0	0	C44	
Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2	0	0	0	C45	
Brain, CNS	4	0	0	0	1	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	C71	
Naso-Oropharynx	3	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	C11	
Oesophagus	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	C15	
Kidney	3	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	C64	

Leukaemia	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	C92
Mouth	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	C06
Larynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	C32
Vulva	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	C51
Vagina	2	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	C52
Ill defined	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	C76
Hodgkin lymphoma	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	C81
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C02
Salivary gland	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C07
Kaposi Sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	C46
Connective tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	C49
Placenta	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C58
Eye	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C69
Endocrine	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C74
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C96

Site	All Ages	ALL MALES																			
		Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	1509	1	2	5	3	6	6	24	36	43	53	87	123	178	230	253	206	150	75	29	
All sites but C44	1063	0	1	5	3	6	5	24	29	37	38	66	88	126	172	186	140	89	33	15	
Prostate	406	1	0	0	0	0	0	0	1	2	5	6	24	49	81	99	76	40	15	8	C61
BCC	320	0	0	0	0	0	1	0	4	4	12	15	30	39	42	47	47	38	27	14	C44
SCC of skin	114	0	0	0	0	0	0	0	3	2	3	6	5	10	16	16	18	22	13	0	C44
Primary site unknown	85	0	0	1	1	1	0	0	1	3	7	8	8	13	10	11	10	9	0	1	C80
Colorectal	78	0	0	0	0	1	0	1	0	4	1	8	9	9	8	15	10	6	6	0	C18
Bladder	61	0	0	0	1	0	0	0	0	1	1	4	3	7	11	8	11	9	5	0	C67
Lung	43	0	0	0	0	1	1	0	1	1	1	3	2	5	7	9	4	5	1	2	C34
Oesophagus	39	0	0	0	0	0	0	0	0	1	2	4	0	6	11	7	4	3	0	1	C15
Melanoma	34	0	0	0	0	0	0	2	2	2	1	1	6	2	2	7	3	2	2	2	C43
Non-Hodgkin lymphoma	34	0	0	1	0	0	0	3	1	5	1	7	5	0	2	3	4	1	0	1	C84
Kaposi Sarcoma	30	0	0	0	0	0	1	2	8	2	6	4	4	2	0	1	0	0	0	0	C46
Pancreas	21	0	0	0	0	0	0	0	1	0	2	1	2	1	3	5	4	1	1	0	C25
Larynx	21	0	0	0	0	0	0	0	0	0	0	3	3	3	8	2	2	0	0	0	C32
Liver & Bile duct	18	0	0	0	0	0	0	0	0	4	1	2	2	1	3	4	0	1	0	0	C22
Kidney	16	0	0	1	0	0	0	1	0	0	1	0	3	3	2	3	1	1	0	0	C64
Stomach	14	0	0	0	0	0	0	2	3	2	1	0	1	1	1	0	1	2	0	0	C16
Other specified	14	0	0	0	0	0	0	1	1	0	0	2	3	4	0	0	3	0	0	0	C63
Skin other	12	0	1	0	0	0	0	0	0	0	0	0	0	3	0	4	1	1	2	0	C44
Testis	12	0	0	0	0	0	1	2	4	0	3	1	0	1	0	0	0	0	0	0	C62
Tongue	11	0	0	0	0	0	0	1	0	0	0	1	0	0	5	3	0	1	0	0	C02
Anus	11	0	0	0	0	0	0	0	3	1	0	0	2	1	2	0	1	1	0	0	C21
Brain, CNS	11	0	1	0	1	0	0	0	0	1	0	2	2	1	1	0	0	2	0	0	C71
Myeloma	11	0	0	0	0	0	0	0	0	0	0	1	0	3	3	2	0	2	0	0	C90
Leukaemia	11	0	0	0	0	1	1	2	0	2	1	0	1	1	0	2	0	0	0	0	C92
Hodgkin lymphoma	10	0	0	1	0	0	0	3	2	0	1	1	1	1	0	0	0	0	0	0	C81

Mouth	9	0	0	0	0	0	0	0	1	1	1	1	2	2	1	0	0	0	0	C06	
Naso-Oropharynx	8	0	0	0	0	0	0	1	0	0	0	0	0	4	2	0	0	1	0	C11	
Breast	8	0	0	0	0	0	0	1	0	1	0	0	1	1	2	0	1	1	0	C50	
Connective tissue	7	0	0	0	0	1	0	0	0	0	0	1	0	3	1	0	0	0	1	C49	
Penis	7	0	0	0	0	0	0	0	0	1	3	1	1	0	0	1	0	0	0	C60	
Eye	7	0	0	0	0	0	0	1	0	1	0	0	1	0	2	0	0	1	1	0	C69
Endocrine	5	0	0	0	0	0	0	0	0	1	0	0	1	2	0	1	0	0	0	C74	
Ill defined	5	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	2	0	0	C76	
Bone	4	0	0	0	0	1	1	1	0	0	0	0	0	1	0	0	0	0	0	C41	
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	C45	
Lip	2	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	C00	
Salivary gland	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	C07	
Thyroid	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	C73	
Gum	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C03	
Small intestine	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C17	
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C96	

Site	ASIAN MALES																		
	All Ages		Unknown Ages																
	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	19	0	0	0	0	0	2	1	0	1	2	0	2	3	4	1	0	1	
All sites but C44	18	0	0	0	0	0	2	1	0	1	2	1	0	2	3	4	1	0	1
Lung	5	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	1	C34
Primary site unknown	3	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	C80
Colorectal	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	C18
Prostate	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	C61
Testis	2	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	C62
Tongue	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C02
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C32
BCC	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C44
Other specified	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	C63
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C67

BLACK MALES

Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	528	1	2	5	2	5	3	16	23	26	30	33	45	75	90	87	50	21	11	4	
All sites but C44	507	0	1	5	2	5	3	16	21	26	27	33	45	71	88	84	48	19	9	4	
Prostate	201	1	0	0	0	0	0	0	1	1	3	3	9	25	45	56	35	12	7	4	C61
Primary site unknown	42	0	0	1	1	1	0	0	1	1	6	4	4	9	6	3	3	2	0	0	C80
Oesophagus	27	0	0	0	0	0	0	0	0	1	1	3	0	5	7	6	2	2	0	0	C15
Kaposi Sarcoma	26	0	0	0	0	0	1	2	7	2	6	2	4	2	0	0	0	0	0	0	C46
Colorectal	24	0	0	0	0	0	0	0	0	1	1	4	3	5	5	5	0	0	0	0	C18
Non-Hodgkin lymphoma	22	0	0	1	0	0	0	2	1	5	1	4	3	0	2	1	2	0	0	0	C84
Lung	15	0	0	0	0	1	0	0	1	1	1	1	2	2	2	2	2	0	0	0	C34
Larynx	12	0	0	0	0	0	0	0	0	0	0	0	3	3	3	2	0	1	0	0	C32
Liver & Bile duct	10	0	0	0	0	0	0	0	0	3	1	2	0	0	3	1	0	0	0	0	C22
Hodgkin lymphoma	10	0	0	1	0	0	0	3	2	0	1	1	1	0	0	0	0	0	0	0	C81
Leukaemia	10	0	0	0	0	1	1	2	0	2	1	0	1	1	0	1	0	0	0	0	C92
Mouth	9	0	0	0	0	0	0	0	0	1	1	1	1	2	2	1	0	0	0	0	C06
Pancreas	9	0	0	0	0	0	0	0	1	0	2	0	2	1	0	2	0	0	1	0	C25
Bladder	9	0	0	0	1	0	0	0	0	0	0	0	3	2	1	2	0	0	0	0	C67
Anus	8	0	0	0	0	0	0	0	2	1	0	0	2	1	2	0	0	0	0	0	C21
SCC of skin	8	0	0	0	0	0	0	0	2	0	0	0	0	1	2	0	1	1	0	0	C44
Stomach	7	0	0	0	0	0	0	2	3	1	1	0	0	0	0	0	0	0	0	0	C16
BCC	7	0	0	0	0	0	0	0	0	0	3	0	0	0	0	1	1	1	1	0	C44
Breast	7	0	0	0	0	0	0	1	0	1	0	0	1	1	2	0	0	1	0	0	C50
Kidney	7	0	0	1	0	0	0	1	0	0	0	0	1	2	0	2	0	0	0	0	C64
Skin other	6	0	1	0	0	0	0	0	0	0	0	0	0	3	0	2	0	0	0	0	C44
Other specified	6	0	0	0	0	0	0	0	0	0	0	0	1	2	2	0	0	1	0	0	C63
Naso-Oropharynx	5	0	0	0	0	0	0	1	0	0	0	0	0	0	2	2	0	0	0	0	C11
Penis	5	0	0	0	0	0	0	0	0	0	1	3	1	0	0	0	0	0	0	0	C60
Myeloma	5	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0	1	0	0	C90

Bone	4	0	0	0	0	1	1	1	0	0	0	0	0	1	0	0	0	0	0	C41
Eye	4	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	0	0	0	C69
Tongue	3	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	C02
Connective tissue	3	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	1	C49
Ill defined	3	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	C76
Salivary gland	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	C07
Melanoma	2	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	C43
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	C45
Brain, CNS	2	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	C71
Endocrine	2	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	C74
Lip	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C00
Small intestine	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C17
Testis	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C62
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C96

Site	COLOURED MALES																		
	All Ages	Unknown Ages																	
	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	22	0	0	0	1	0	0	0	1	3	1	3	4	3	2	2	0	1	
All sites but C44	18	0	0	0	1	0	0	0	0	2	1	3	3	3	2	2	0	0	
Prostate	8	0	0	0	0	0	0	0	0	0	1	2	1	1	1	2	0	0	C61
BCC	4	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	1	C44
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C02
Stomach	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	C16
Colorectal	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C18
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C25
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C32
Connective tissue	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C49
Kidney	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C64
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C67
Brain, CNS	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	C71
Non-Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C84

WHITE MALES

Site	All Ages	Unknown Ages	0-4	5-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	940	0	0	0	0	1	3	6	12	16	21	49	75	100	134	160	150	126	64	23	
All sites but C44	520	0	0	0	0	1	2	6	7	10	10	29	41	52	79	96	86	67	24	10	
BCC	308	0	0	0	0	0	1	0	4	4	8	14	29	39	41	46	46	37	26	13	C44
Prostate	195	0	0	0	0	0	0	0	0	1	2	3	13	22	35	41	40	26	8	4	C61
SCC of skin	106	0	0	0	0	0	0	0	1	2	3	6	5	9	14	16	17	21	12	0	C44
Colorectal	51	0	0	0	0	1	0	1	0	3	0	4	6	4	3	9	8	6	6	0	C18
Bladder	50	0	0	0	0	0	0	0	0	1	1	4	0	5	10	5	10	9	5	0	C67
Primary site unknown	39	0	0	0	0	0	0	0	0	2	0	3	4	4	4	8	6	7	0	1	C80
Melanoma	32	0	0	0	0	0	0	2	2	1	1	1	6	1	2	7	3	2	2	2	C43
Lung	23	0	0	0	0	0	1	0	0	0	0	2	0	3	4	6	1	4	1	1	C34
Oesophagus	12	0	0	0	0	0	0	0	0	0	1	1	0	1	4	1	2	1	0	1	C15
Pancreas	11	0	0	0	0	0	0	0	0	0	0	1	0	0	2	3	4	1	0	0	C25
Non-Hodgkin lymphoma	11	0	0	0	0	0	0	1	0	0	0	2	2	0	0	2	2	1	0	1	C84
Testis	9	0	0	0	0	0	1	1	2	0	3	1	0	1	0	0	0	0	0	0	C62
Liver & Bile duct	8	0	0	0	0	0	0	0	0	1	0	0	2	1	0	3	0	1	0	0	C22
Kidney	8	0	0	0	0	0	0	0	0	0	1	0	2	0	2	1	1	1	0	0	C64
Brain, CNS	8	0	0	0	0	0	0	0	0	0	0	2	2	1	1	0	0	2	0	0	C71
Larynx	7	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2	1	0	0	0	C32
Other specified	7	0	0	0	0	0	0	0	1	0	0	1	1	2	0	0	2	0	0	0	C63
Tongue	6	0	0	0	0	0	0	1	0	0	0	0	0	0	2	2	0	1	0	0	C02
Stomach	6	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	2	0	0	C16
Skin other	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	2	0	C44
Myeloma	6	0	0	0	0	0	0	0	0	0	0	1	0	2	0	2	0	1	0	0	C90
Kaposi Sarcoma	4	0	0	0	0	0	0	0	1	0	0	2	0	0	0	1	0	0	0	0	C46
Naso-Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	C11
Anus	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	C21
Connective tissue	3	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	C49

Eye	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	C69
Endocrine	3	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	C74
Penis	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	C60
Thyroid	2	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	C73
Ill defined	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	C76
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C00
Gum	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C03
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C45
Breast	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C50
Leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C92